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ABSTRACT 
The Metabolic Effects of Orlistat and Rosiglitazone on Insulin action in a group 
of Chinese Patients affected by the Metabolic Syndrome 
submitted by 
LOH Shwu Chun 
for the Degree of Master in Philosophy in Pharmacy 
at 
THE CHINESE UNIVERSITY OF HONG KONG in (June 2005) 
Individuals with the metabolic syndrome are at increased risk for developing 
diabetes mellitus and cardiovascular disease. They also have an increased mortality 
from cardiovascular diseases and all causes. Current concepts of the metabolic 
syndrome represent the convergence of two merging streams of research. Some 
investigators viewed the metabolic syndrome as a result of obesity and its metabolic 
complications. On the other hand, insulin resistance is perceived as the major 
underlying cause for the metabolic syndrome. 
Although the effects of pharmacotherapy on improving the metabolic 
syndrome are widely investigated overseas, local work is relatively lacking. This 
study aimed to examine the effects and assess the changes of cardiovascular risk 
factors of orlistat and rosiglitazone in a group of Chinese patients affected by the 
metabolic syndrome. Both agents do not reduce plasma glucose levels directly. 
Instead, they act by either directly increasing the body's insulin sensitivity as for 
rosiglitazone, or indirectly by reducing body weight leading eventually to improved 
metabolic control as for orlistat. 
A prospective, 6-months randomized single-blinded placebo-controlled study 
was conducted involving 63 Chinese participants with type 2 diabetes or impaired 
glucose tolerance, aged > 18 years with a BMI > 23kg/m^ were administered orally 
120 mg orlistat three times daily, rosiglitazone 2mg twice daily or placebo three 
times daily. Changes in clinical and metabolic parameters indicative of the metabolic 
/ / 
syndrome were monitored, including body weight, glycaemic control, lipid levels 
and drug tolerability. 
There were 20 individuals in the rosiglitazone group and 19 individuals in 
both the orlistat and placebo groups. The orlistat group demonstrated improved lipid 
profiles, especially on the reduction of total cholesterol (12% p < 0.0005) and LDL-
cholesterol (21%, p = 0.0002). This was accompanied by an improvement in the 
fasting insulin levels (p = 0.07) and HOMA scores (p = 0.026). In comparison, the 
rosiglitazone group exhibits maximum improvements in fasting insulin (p = 0.004)， 
2hr-post OGTT insulin (p = 0.004) and HOMA scores (p = 0.005). However, there is 
an increase from baseline in the LDL-cholesterol levels (12%), body fat (3.7%) and 
hip circumference (1.5%). 
To prevent progression to type 2 diabetes mellitus and its complications, 
early detection and implementation of appropriate treatment strategies for the 
metabolic syndrome is crucial. Other than dietary therapy and exercise, the use of 
rosiglitazone especially in the treatment of insulin-resistant patients with IGT or type 
2 diabetes is practical, since most of its problems derived from insulin resistance. On 
the other hand, orlistat, with its effects on weight, lipids and glucose, may be a useful 
treatment modality, especially in obese patients insulin-resistant patients. 
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ALT Alanine Transaminase 
AST Aspartate Aminotransferase 
ATP Adenosine Triphosphate 
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BP Blood Pressure 
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D.O.B. Date of Birth 
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Hb lAc Glycosylated Haemoglobin 
HDL-cholesterol High-density Lipoproten Cholesterol 
HOMA Homeostatic Model Assessment 
IDF International Diabetes Federation 
IFG Impaired Fasting Glucose 
IGF-I Insulin-like Growth Factor-I 
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RCCA Right Common Carotid Artery 
STOP-NIDDM Study to Prevent Non-Insulin dependent diabetes mellitus 
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Introduction 1 Introduction 
Over the last decade, investigators have given increased attention to the complex 
role of multiple metabolic abnormalities in the development of related chronic 
diseases such as type 2 diabetes mellitus and cardiovascular disease. One of the first 
people to introduce the metabolic syndrome in scientific literature was Camus in 
1966. However, this entity did not receive much interest until Reaven in 1988, 
introduced the term "Syndrome X,，，which referred to a group of related disorders, 
associated with increased risk of both type 2 diabetes and cardiovascular disease, 
characterised by impaired glucose tolerance, dyslipidaemia and hypertension. 
Insulin resistance, located primarily in skeletal muscle and limited to non-
oxidative glucose disposal was cited as the primary underlying mechanism of the 
syndrome. Insulin resistance is an impaired biological response to the effects of 
exogenous or endogenous insulin (on glucose, lipids, metabolic activity or vascular 
endothelial function). Hyperinsulinaemia, which accompanies insulin resistance, can 
maintain sufficiently normal glucose metabolism as long as pancreatic P-cell 
function remains normal. However, in many patients, p-cell deficiencies slowly 
develop and type 2 diabetes occurs as a result of impaired glucose metabolism. 
(Alberti KG et al. 1998). 
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The combination of insulin resistance and compensatory hyperinsulinaemia were 
considered necessary for the development of other lipid and non-lipid abnormalities. 
DeFronzo and Ferrannini 1991 also stated insulin resistance as the central feature of 
the syndrome. Syndrome X is also known as to as the metabolic syndrome, the 
metabolic cardiovascular syndrome, atherothrombogenic syndrome, the insulin 
resistance syndrome or plurimetabolic syndrome. However, the terms "insulin 
resistance" or "metabolic syndrome" are now most widely accepted for this clinical 
entity. For the purposes of this thesis, the metabolic syndrome will be adopted. 
1.1 Definition and diagnostic criteria of the metabolic syndrome 
Although it has been the subject of intense discussion for several years, there is 
still no easy definition for the metabolic syndrome as it is not a unique clinical 
disease. Rather, it is a metabolic milieu whereby a number of cardiovascular risk 
factors arise and interact synergistically. 
Several expert panels have recently provided some uniformity by proposing similar 
metabolic components within the syndrome (Table 1.1). Although these guidelines 
are consistent in that there is a focus on insulin resistance/hyperinsulinaemia, 
hyperglycaemia, obesity (especially central/upper body distribution), dyslipidaemia 





















































































































































































































































































































































































































































































































































































































































































































































































































































Chapter 1 , , ^ Introduction 
considerable disparity within the expert panel criteria for the individual metabolic 
traits, as well as the syndrome itself. 
It was recognised that existing guidelines put forward by the World Health 
Organisation (WHO) and National Cholesterol Education Program - Third Adult 
Treatment Panel (NCEP ATP III) were never intended to provide exact diagnostic 
criteria for identifying individuals with metabolic syndrome in clinical practice. 
However, there is a need for a single, universally accepted diagnostic tool that is 
easily to apply in clinical practice. Hence, the International Diabetes Federation (IDF) 
held a press release in April 2005 to launch its worldwide definition of the metabolic 
syndrome (Table 1.2). This new definition addresses both clinical and research needs, 
providing an accessible, diagnostic tool suitable for worldwide use and establishing a 
comprehensive list of additional criteria that should be included in epidemiological 
studies and other research into the metabolic syndrome. Although the pathogenesis 
of the metabolic syndrome and each of its components is complex and not well 
understood, central obesity and insulin resistance are acknowledged by the IDF as 
important causative factors. Central obesity is most easily measured by waist 
circumference, which is gender and ethnic-group specific. The IDF also specifies the 
recommendations for these specifications in its definition. 
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Table 1.2: The IDF consensus worldwide definition of the metabolic syndrome 
for use in clinical practice (IDF 2005) 
For a person to be defined as having the metabolic syndrome, they must have: 
Central obesity 
• Waist circumference for Chinese > 90 cm in males 
> 80 cm in females 
Plus any TWO of the following four factors: 
• triglyceride levels OR > 1.7 mmol/L 
specific treatment for this lipid 
abnormality 
• i HDL-cholesterol < 1.03 mmol/L in males 
< 1.29 mmol/L in females 
• T blood pressure OR systolic BP > 130 or diastolic > 85 mm 
treatment of previously diagnosed Hg 
hypertension 
•个 fasting plasma glucose OR > 5.6 mmol/L 
previously diagnosed type 2 diabetes 
1.2 Clinical States of the metabolic syndrome 
The metabolic syndrome is characterized by many metabolic abnormalities, 
including impaired glucose tolerance, insulin resistance, dyslipidaemia, hypertension, 
central obesity, coagulation anomalies favouring thrombosis, hypemricaemia and 
occasionally, polycystic ovary syndrome. Together, these abnormalities create a 
metabolic environment that increases the risks of macrovascular atherosclerotic 
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abnormalities, such as stroke, heart attack, peripheral vascular disease, as well as 
renal failure. 
I.2.1 Impaired glucose tolerance (IGT) and Impaired Fasting Glucose (IFG) 
The expert committee on the Diagnosis and Classification of Diabetes 
Mellitus recognized an intermediate group of subjects whose glucose levels, although 
not meeting criteria for diabetes, are nevertheless too high to be considered normal 
(Table 1.3). This group is defined as having FPG levels > 5.6 mmol/L but < 7.0 
mmol/L or 2-h values in the oral glucose tolerance test (OGTT) of 7.8 mmol/L but < 
II.1 mmol/L (American Diabetic Association 2004). 
Patients with IFG and/or IGT are now referred to as having "pre-diabetes" 
indicating the relatively high risk for development of diabetes in these patients. 
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Table 1.3: Criteria for the diagnosis of diabetes (American Diabetes Association  
2004) 
Normoglycaemia IFG or IGT Diabetes 
FPG (mmol/L) <5.6 >5.6 and <7.0 (IFG) > ^ 0 
O G T T t 
2h-post glucose <7.8 > 7.8 and < 11.1 (IGT) 2 11.1 
(mmol/L) Symptoms of 
diabetes and RPG 
> 11.1 mmol/L 
In the absence of unequivocal hyperglycaemia, a diagnosis of diabetes must be confirmed, on a 
subsequent day, by measurement of FPG, 2-h post glucose or random plasma glucose (if symptoms 
are present). The FPG test is greatly preferred because of ease of administration, convenience, 
acceptability to patients, and lower cost. Fasting is defined as no caloric intake for at least 8h. 
卞 This test requires the use of a glucose load containing the equivalent of 75g anhydrous glucose 
dissolved in water, 
1.2.2 The metabolic syndrome and type 2 diabetes mellitus 
It has been proposed that the metabolic syndrome is a powerful determinant 
of type 2 diabetes mellitus and cardiovascular disease (Reaven GM 1988 and 
Defronzo RA et al 1991). 
The ADA defined diabetes mellitus as "a group of metabolic diseases 
characterized by hyperglycaemia resulting from defects in insulin secretion, insulin 
action, or both". Chronic hyperglycaemia of diabetes will cause long-term damage, 
dysfunction and failure of various organs, especially the eyes, kidneys, nerves, heart 
and blood vessels (Reaven GM, 1988，DeFronzo Ra 1991，UKPDS 23, 1998). 
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The last two decades have seen a huge global increase in the diabetic patients. 
Currently，it is estimated that 150 million people in the world suffering from diabetes. 
This number is expected to increase to 300 million by the year 2025 (Kumanyika S et 
al 2002). The metabolic syndrome is now recognized as an early metabolic 
abnormality that precedes the development of type 2 diabetes (Alberti KG et al 1998). 
In the FINRISK study cohort, the prevalence of the metabolic syndrome was 91.5 
and 82.7% in subjects with type 2 diabetes in men and women respectively (Ilanne-
Parrikka P et al 2004). Prevention of type 2 diabetes should therefore aim to prevent 
and treat several components of the metabolic syndrome simultaneously. 
1.2.3 Dyslipidaemia 
Both the decrease in HDL-cholesterol and increase in LDL-cholesterol are 
well-established risk factors for coronary artery disease (CAD) and other 
macrovascular complications (Castelli WP et al 1989). The characteristic lipid profile 
in a Type 2 DM patient includes decreased serum HDL-cholesterol, increased serum 
VLDL-cholesterol and an increase in triglycerides. 
A close relationship between hyperinsulinaemia and hypertriglyceridaemia 
has been described in population-based studies in healthy normal weight subjects 
(Zavaroni et al 1989，Orchard TJ et al 1983). In 1991，Defronzo and Ferrannini 
extended the concept of hyperinsulinaemia as one of the cause of an atherogenic 
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plasma lipid profile. They explained that elevated plasma insulin concentrations 
enhance VLDL-cholesterol synthesis, leading to hypertriglyceridaemia. Progressive 
elimination of lipid and apolipoproteins from the VLDL particle leads to an 
increased formation of intermediate-density and low-density lipoprotein, both of 
which are atherogenic. Plasma insulin and HDL-cholesterol concentrations was 
inversely correlated (Orchard TJ et al 1983 and Golay A et al 1987). Therefore, 
hyperinsulinaemia is associated with a reduced HDL-cholesterol levels and increased 
risk for CAD. Consequently, it is important to recognize that insulin resistance 
represents the basic underlying defect in abnormal plasma lipid profile (Defronzo RA 
and Ferrannini E 1991). 
In addition, insulin, independent of its effects on blood pressure and plasma 
lipids, is known to be atherogenic (Jarret RJ 1988). The hormone enhances 
cholesterol transport into arteriolar smooth muscle cells and increase endogenous 
lipid synthesis by these cells. Insulin also augments collagen synthesis in the vascular 
wall. Since insulin itself is a growth-promoting substance, it may bind to receptors of 
various other growth factors, including Insulin-like Growth Factor I (IGF-I)，which 
cause cells to proliferate and thereby contribute to the atherosclerotic process (Sinha 
MK et al 1989). The major effects of insulin on arterial tissues are summarized in 
Table 1.4. 
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of Insulin on arterial tissues * 
Smooth muscle cells proliferation 
Enhanced cholesterol synthesis and LDL-receptor activity 
Build-up if triglycerides and free fatty acids 
Increased formation and decreased regression of lipid plaques 
Stimulation of connective tissue synthesis 
* Adapted from DeFronzo RA and Ferrannini E 1991 
1.2.4 Hypertension 
Elevated blood pressure is included in most definitions of the metabolic 
syndrome, but its relation to the syndrome is complex. The mechanism and 
pathophysiology of hypertension are associated with the metabolic abnormalities 
seen in the metabolic syndrome (Table 1.5). Because of the compensatory 
hyperinsulinaemia caused by insulin resistance, the sympathetic nervous system is 
stimulated, causing vasoconstriction, increased cardiac output, and renal absorption 
of sodium, which in turn, leads to elevated blood pressure sufficient to override the 
direct normal vasodilating action of insulin in obese and hypertensive patients. 
Insulin may also indirectly increase blood pressure by decreasing the 
signaling processes that are important for vascular relaxation (DeFronzo RA et al 
1991’ Cranford LS 2003). Insulin, by actions on IGF-I, may cause the hypertrophy of 
the vascular wall and narrowing of the lumen of the resistance vessels involved in the 
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regulation of systemic blood pressure, thus, contributing to the development of 
hypertension and atherogenesis (DeFronzo RA et al 1991). 
Mechanisms by which insulin can elevate blood pressure;  
Kidney sodium retention 
Sympathetic nervous system activation 
Enhanced fluxes of Na+ and Ca+ into vascular smooth muscle cells, leading to an 
increased vascular sensitivity to the vasoconstrictor effect of pressor amines 
Proliferation of arteriolar smooth muscle cells 
1.2.5 Obesity 
In non-diabetic patients, excessive calories and weight gain will result in the 
body being markedly resistant to the action of insulin (Sims EAH et al 1973). Many 
investigators have shown that using the euglycaemic insulin-clamp technique, tissue 
sensitivity to insulin declines by approximately 30 - 40% when an individual 
becomes > 35 -40 % over ideal body weight (Bonadonna R et al 199 and Golay A et 
al 1988). Cross-sectional data (Park YW et al 2003) indicate that the dose response 
of body mass index versus prevalence of metabolic syndrome is sigmoidal, with a Km 
approximately 26 kg/m^ in women and 28 kg/m^ in men, which suggests a critical 
impact of mild degrees of overweight. 
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The association between obesity and type 2 diabetes mellitus is recognized 
for decades, since obesity is able to engender insulin resistance. Approximately 30 to 
50% of obese individuals will develop diabetes mellitus or impaired glucose 
tolerance (Hauner H, 1999), and up to 90% of patients with type 2 diabetes mellitus 
are overweight or obese (Tremble JM et al. 1999). The medical consequences of 
obesity are well recognized and, in patients with diabetes, may contribute to other 
comorbidities. 
The relationship between obesity and insulin resistance is seen across all ethnic 
groups and is evident across the full range of body weights. Large epidemiologic 
studies reveal that the risk for diabetes, and presumably the metabolic syndrome, 
rises as body fat content increases from the very lean to the very obese, implying that 
the “dose，，of body fat has an effect on insulin sensitivity across a broad range 
(Colditz GA et al, 1990). Although this relationship is seen with measures of 
adiposity such as BMI, which reflect general adiposity, it is critical to realize that all 
sites of adiposity are not equal in this regard. Central (intra-abdominal) deposit of fat 
are much more strongly linked to insulin resistance, type 2 diabetes, and 
cardiovascular disease than are peripheral (gluteal/subcutaneous) fat depots. 
Although obesity per se is associated with increased morbidity, the association is 
even stronger for truncal fat and particularly visceral fat (Vague J 1956, Pi-Sunyer 
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FX 1993). It was also demonstrated that visceral fat accumulation is associated with 
dyslipidaemia, hypertension, insulin resistance and albuminuria in Chinese patients 
with Type 2 diabetes mellitus (Anderson PJ et al 1997). When compared with 
subcutaneous adipose tissue, visceral adipocytes exhibit increased sensitivity to the 
lipolytic effects of catecholamines and reduced sensitivity to the antilipolytic effects 
of insulin (Chen YDI et al, 1987). Both genetic and environmental factors contribute 
to the development of obesity and the distribution of body fat. 
1.3 Effects of weight loss on the metabolic syndrome 
Lifestyle modification is the cornerstone of treatment for the metabolic 
syndrome. Recent treatment guidelines for the metabolic syndrome have emphasized 
the clinical utility of diagnosis and an important treatment role for "therapeutic 
lifestyle change", incorporating moderate physical activity. Recent review has 
considered exercise training effective in the treatment of insulin resistance and 
related components of the syndrome. However, the evidence for exercise effects has 
been considered less consistent for dyslipidaemia, impaired glucose regulation and 
hypertension, unless exercise training is combined with appropriate dietary 
modifications to achieve weight loss. Thus, an effective lifestyle modification 
includes both diet and exercise therapy, aimed at achieving a net negative energy 
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balance by decreasing energy intake and increasing energy expenditure, with the goal 
of decreasing both body weight and insulin resistance (Miranda PJ et al 2005). 
A number of clinical trials have approached the problem of reducing insulin 
resistance by increasing the level of physical activity, which has the potential 
benefits of enhancing insulin sensitivity and enabling increased weight loss. The Da 
Qing IGT and Diabetes Study, the Finnish Diabetes Prevention Study, and the 
Diabetes Prevention Program (DPP), demonstrated that modest weight loss achieved 
by lifestyle changes (diet and exercise) can significantly reduce the risk of 
developing type 2 diabetes in obese patients with IGT (Tuomilehto J et al, 2001, 
Knowler WC et al, 2002.). Lifestyle intervention improved CVD risk factor status in 
the DPP study: triglyceride levels fell significantly more with intensive lifestyle 
intervention while HDL-cholesterol and LDL-particle size increased significantly, 
sustained over the course of the study (Diabetes Prevention Program Research Group 
2005). Weight reduction of 5 to 10% improves serum glucose (Wing R et al. 1994) 
and insulin levels (Watts NB et al. 1990). The Swedish Obese Subjects (SOS) study 
has demonstrated that large weight losses in obese patients are associated with an 
8O0/0 reduction in the 8-year incidence of diabetes (Sjostrom CD et al, 2002). 
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1.4 Ethnic differences in the prevalence of the metabolic syndrome 
Since the prevalence of hypertension, insulin resistance and glucose 
intolerance usually increase with increasing age, the prevalence of the metabolic 
syndrome will probably also rise in the aging society. 
According to the ATP III definition, an estimated of > 20% of American adults 
have the metabolic syndrome. Mexican Americans had the highest age-adjusted 
prevalence of 31.9%. Among African-Americans, women had about a 57% higher 
prevalence than men did. Using the 2000 census data, about 47 million US residents 
have the metabolic syndrome (Ford ES et al 2002). 
In the Finnish population, using the WHO criteria for the metabolic syndrome, 
it is estimated that the metabolic syndrome was present in 38.8 % of men and 22.2 % 
of women in the FINRISK study cohort. The study also reported a prevalence of 84.8 
and 65.4 % in subjects with IGT affected with the metabolic syndrome (lilanne-
Parrikka P et al 2004). In the Finnish Diabetes Prevention Study (DPS), 78.4 % of 
men and 72.2 % of women with IGT had the metabolic syndrome (Tuomilehto J et al 
2001). 
In an urban Korean population, when adopting the ATP III criteria, the 
prevalence of the metabolic syndrome was 16.0% in men and 10.7% n women aged 
30 - 80 years. However, when the waist circumference is reduced from 102 to 90cm 
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in men and 88 to 87cm in women, the prevalence of the metabolic syndrome 
increased to 29.0 and 16.8% respectively (Oh JY, et al 2004). 
1.5 Treatment of the metabolic syndrome 
Early recognition is important to the healthcare provider as it is critical to 
effective, long-term, comprehensive patient management. Prevention of the 
metabolic syndrome and treatment of its main characteristics are now considered of 
utmost importance in order to combat the epidemic of type 2 diabetes mellitus and to 
reduce the increased risk of cardiovascular disease and all-cause mortality (Foster 
DW 1989). 
In the ACEP III report 2001, the National Cholesterol Education Program 
(NCEP) Expert Panel acknowledged the metabolic syndrome as one potential 
secondary target of therapy. It stated that management of the metabolic syndrome has 
a two-fold objective including the reduction of underlying causes and treating 
associated nonlipid and lipid risk factors if they persist despite the recommended 
lifestyle therapies (Executive summary of the third report of the NCEP Expert Panel 
on Detection, Evaluation, and Treatment of high blood cholesterol in adult 2001). 
Treatment must address the multipathologic process of the metabolic syndrome, with 
each component identified and aggressively targeted for treatment. 
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Introduction Table 1.6: Treatment of the metabolic syndrome 
• Treat underlying causes (i.e. obesity and physical inactivity): 
- Intensifying weight management 
- Increase physical activity; and 
• Treat associated nonlipid and lipid risk factor if they persist despite these 
lifestyle therapies: 
- Treat hypertension 
一 Use aspirin for CHD patients to reduce prothrombotic state 
一 Treat elevated triglycerides and/or low HDL-cholesterol 
1.6 Oral Antidiabetic agents and their failure in the metabolic syndrome 
A number of pharmacological therapies can be used for the treatment of the 
metabolic syndrome, but the results of most of the available therapies are often 
unsatisfactory. 
1.6.1 Sulphonylureas 
The sulphonylureas are very commonly used for type 2 diabetes mellitus. 
These have been available in the United States since 1954. Sulphonyureas binds to 
the sulphonylurea receptor on pancreatic p-cells. This ultimately leads to insulin 
secretion and hence, allow for insulin release at lower glucose thresholds than normal 
(Zimmerman BR. 1997). They partially reverse the attenuated insulin secretion that 
characterizes type 2 diabetes. Understandably, circulating insulin concentrations are 
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increased. As a result and despite the presence of insulin resistance, glucose 
concentrations fall. 
Given the epidemiological association between hyperinsulinaemia and 
cardiovascular disease, some have raised concerns that sulphonylureas increase 
cardiovascular morbidity (Wilson et al 2001, Ashcroft et al 1999)，which is already a 
great concern in the metabolic syndrome. But in the UK Prospective Diabetes Study 
1998 (UK Prospective Diabetes Study Group 1998)，increased mortality was not 
shown. Due to these agents' mechanism of action, there is a concern is their potential 
to exhaust P-cell function. However, as demonstrated by in the UKPDS, the 
inexorable decline in p-cell function may be an underlying characteristic of the 
diabetic state itself, independent of treatment modality. Of more practical concern, 
sulphonylurea therapy is associated with weight gain, especially problematic in a 
group of frequently overweight patients, and hypoglycaemia. Therefore, 
sulphonylurea therapy is not recommended in the metabolic syndrome. 
1.6.2 Biguanides 
In contrast to the sulphonylureas, metformin, the only biguanide available, 
does not stimulate insulin secretion (Johansen K et al. 1999). The precise mode of 
action of metformin remains somewhat controversial, but its predominant effect is to 
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reduce the hepatic glucose production in the presence of insulin (Hundal RS et al. 
2000). It is therefore considered an insulin sensitiser. 
Metformin monotherapy however is associated with weight loss (or no 
weight gain) and much less hypoglycaemia than sulphonylurea therapy (Johansen K. 
1999). Over a period of years, weight gain for diabetic patients on metformin was 
slower than that for patients on sulphonylureas or insulin. Because of the lack of p-
cell stimulation, circulating insulin concentrations tend to decline, which may 
provide a cardiovascular advantage. Other nonglycemia benefits included decreases 
in lipid levels (LDL-cholesterol and triglycerides) and antifibrinolytic factor 
plasminogen activator inhibitor-1. 
The DPP also showed significant decreases in the rate of development of new 
type 2 diabetes cases, with 7.8% per year of the metformin group, which is a 31% 
reduction. The DPP has also demonstrated that metformin is effective at slowing 
metabolic deterioration in individuals with impaired glucose tolerance (Knowler et al 
2002). Thus, metformin is a candidate drug for treatment of the glycaemic 
components of the metabolic syndrome. However, there is a need for additional 
therapies after several years of used as shown in the UKPDS, as p-cells failure also 
occurs in patients who are treated with metformin (UK Prospective Diabetes Study 
Group 1998). 
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1.6.3 Alpha-Glucosidase Inhibitors 
These agents, represented by acarbose and miglitol, is the sole drug class not 
targeted at a specific pathophysiological defect of type 2 diabetes mellitus. These 
drugs competitively inhibit a-glucosidase at the small intestinal epithelium, hence 
preventing the breakdown of disaccharides and more complex carbohydrates, 
resulting in delay intestinal carbohydrate absorption and mitigate postprandial 
glucose excursions (Lebowitz HE 1998). 
The a-glucosidase inhibitors has a considerably less efficacy as compared to 
either the sulphonylureas and metformin, exerting their greatest effect on pos t -prania l 
glucose levels. However, this effect on fasting blood glucose levels is small 
(Hoffman J et al 1997’ Chiasson JL et al 1994). Despite that, a-glucosidase inhibitors 
are still attractive as they are essentially nonsystemic and not a s soc ia ted with 
hypoglycaemia and weight gain. Nonglycaemic advantages included small 
reductions in triglycerides and postpranial insulin levels (Scott R et al 1999). 
In the Study to Prevent Non-Insulin Dependent Diabetes Mellitus (STOP-
NIDDM) used acarbose to test the hypothesis that this agent might prevent the 
development of Type 2 diabetes mellitus in individuals with metabolic syndrome and 
was subsequently found to work successftilly. Only 32% of patients taking acarbose 
developed diabetes, compared with 42% randomized to placebo (Chiasson JL et al. 
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2002). However, there have been no studies that have examined long-term 
effectiveness of these agents in reducing chronic complications. 
1.6.4 Peroxisome Proliferator-Activated receptors (PPARs) 
The discovery of nuclear peroxisome proliferator-activated receptors (PPARs) 
and subsequent insight into their role in several metabolic pathways was a major 
breakthrough in our understanding of pathophysiological mechanisms underlying the 
metabolic syndrome (Vamecq J et al. 1999). PPARs are ligand-activated 
transcription factors belonging to the nuclear receptor superfamily (Lemberger T et 
al, 1996). As transcription factors, PPARs regulate the expression of numerous genes 
and affect glycaemic control, lipid metabolism, vascular tone and inflammation. In 
humans, PPAR receptors are found in key target tissues for insulin action such as 
adipose tissue, skeletal muscle and liver. 
Activation of PPARy nuclear receptors regulates the transcription of insulin-
responsive genes involved in the control of glucose production, transport, and 
utilization (Figure 1.1). In addition, PPARy-responsive genes also participate in the 
regulation of fatty acid (Wilson TM et al 2000). 
Three subtypes of PPARs are known: PPAR-a, PPAR-丫 and PPAR-5. PPAR-
Y is found in adipose tissue, pancreas, skeletal muscle and vasculature (Loviscach M 
et al, 2000). Thiazolidinediones are potent synthetic ligands for PPAR-y activation. 
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1.6.4.1 Thiazolidinediones 
Thiazolidinediones are a new class of drugs that act primarily by improving 
insulin sensitivity in different target tissues such as liver, skeletal muscle and adipose 
tissue. They have been shown to improve glycaemic control in patients with type 2 
diabetes and appear to have favourable direct effects on other components of the 
metabolic syndrome because of the role ofPPAR-y in vascular physiology. 
Thiazolidinediones are pharmacological ligands for PPAR-y. When activated, 
P P A R - Y binds with response elements on D N A , altering transcription of a variety of 
genes that regulate carbohydrate and lipid metabolism (Mudaliar S et al. 2001). The 
most prominent effect is increased insulin-stimulated glucose uptake by skeletal 
muscle cells. Thus, these agents decrease insulin resistance in peripheral tissues and 
hepatic glucose production (Petersen KF, et al. 2000). 
Thiazolidinediones also have a beneficial effect on the dyslipidaemia 
associated with the metabolic syndrome: they decrease levels of triglycerides and 
free fatty acids, and they increase HDL-cholesterol levels (Komers R et al 1998). 
Thiazolidinediones do not lower the total LDL-cholesterol level but produce an 
increase in the level of large, buoyant LDL particles and a decrease in the number of 
small，dense LDL particles (Lebovitz HE 2002). 
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Figure 1.1. The central role of peroxisome proliferator-activated receptor 
(PPAR)-Y in vascular physiology. 
Insulin Resistance 
Cytokines ^ PPAR-y ——二 ^ Pancreatic p-cell 
(Inflammation) ！：^ ~ dysfunction 
Hyperinsulinaemia + glucose intolerance 
PPAR-activation triggers: 
• T glucose disposal and uptake 
• I glucose production 
• i insulin receptor expression 
• i HbAlc 
Thiazolidinediones are chemically and functionally unrelated to other classes 
of oral antihyperglycaemic agents. Two compounds in this class are currently 
available for clinical use, namely rosiglitazone, which was approved by the United 
States (US) Food and Drug Administration (FDA) in May 1999，and pioglitazone, 
which was approved in July 1999. Troglitazone, the first thiazolidinedione, was 
marketed in the US from March 1997 until it was withdrawn in March 2000 because 
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of rare idiosyncratic hepatocellular injury (Murphy EJ et al., 2000). In Hong Kong, 
rosiglitazone is generally available as a prescription only item, but for pioglitazone, 
there is restricted access to selected government-based hospitals. 
1.6.4,1,1 Rosiglitazone 
Rosiglitazone is a member of the thiazolidinedione group of oral 
antihyperglycaemic agents. It increases the sensitivity of skeletal muscle, liver and 
adipose tissue to insulin without directly stimulating insulin secretion from 
pancreatic P-cells (Whitecomb RW et al 1995 and Day C 1999). 
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Figure 1.2. Chemical Structure of Rosiglitazone maleate 
1.6.4.1.1.1 Mode Of Action 
Rosiglitazone is a highly selective and potent agonist PPAR-y. Binding of 
rosiglitazone to PPAR-y results in reduced plasma glucose levels and endogenous 
glucose production, and increased glucose clearance in patients with type 2 diabetes 
mellitus. 
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Rosiglitazone has several pharmacodynamic effects that could ameliorate the 
increased risk of cardiovascular disease in patients with the metabolic symptoms. 
Insulin resistance is decreased, as are plasma free fatty acids and plasma levels of 
small dense atherogenic LDL-C particles, despite an initial overall increase in total 
LDL-C. Levels of the atheroprotective large HDL particles are increased (Thomas JC 
et al. 2001). Changes in triglyceride levels are small and often not statistically 
significant (Khan MA et al. 2002, Lebovitz et al 2001). 
In a clinical study reported as an abstract, diastolic blood pressure is 
significantly decreased (-2.3 mmHg; p < 0.01 vs. baseline) and systolic blood 
pressure is slightly decreased in 66 rosiglitazone recipients, when compared to 63 
glibenclamide recipients (Bakris GL et al 2000). 
While an increase in bodyweight has been associated with rosiglitazone, the 
increase is seen in subcutaneous fat depots rather than in visceral fat and hepatic fat 
depots are decreased (Carey DG et al 2000 and Banerji M et al 2001). Increases in 
bodyweight from baseline were similar (about 2kg) and significant (pO.Ol) on 
administration of rosiglitazone for 4 months in a randomized non-blinded study of 
patients with type 2 diabetes mellitus (Khan MA et al. 2002). 
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Rosiglitazone has beneficial effects on pancreatic p-cell function in obese and 
non-obese patients with type 2 diabetes mellitus, suggesting possible positive effects 
on disease progression. 
Rosiglitazone appears to be effective in patients from differing ethnic groups 
such as Indo-Asian, Mexican and Chinese (Bamett AH et al 2001, Gomez-Perez FJ 
et al 2002’ Zhu X et al 2001) and in elderly patients (Beebe KL 1999). 
1.6.4.1.1.2 Adverse Effects & current status 
Rosiglitazone is generally well tolerated. Adverse effects occurring at an 
incidence of > 5% included upper respiratory tract infection, injury and headache. It 
can also cause fluid retention, in a dose-related manner (SmithKline Beecham 
Pharmaceuticals, Prescribing information 2001). This effect may, in part, be a result 
of increased insulin-stimulated vasodilatation as a consequence of increased insulin 
sensitivity. As with other thiazolidinediones and as seen with intensive therapy with 
sulphonylureas or insulin in the UKPDS study, rosiglitazone is associated with 
significant increases in bodyweight. However, subcutaneous fat depots appear to be 
targeted rather than hepatic or visceral fat depots, and waist-to-hip ratios appear 
largely unaffected (Carey GD et al 2000 and Banerji M et al 2001). 
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Oral rosiglitazone is indicated in the US and Canada for use as monotherapy in 
non-obese and obese type 2 diabetes, in whom diabetes not adequately controlled by 
diet and exercise. In Europe, it can be used as monotherapy if patients is 
contraindicated for or intolerant of metformin (Wagstaff et al 2002’ Krentz AJ et al 
2005). When used as monotherapy, the recommended starting dosage is 4mg once 
daily or 2mg twice daily. After 8 to 12 weeks, the dosage may be increased to 
8mg/day (given in one or two daily doses) if response is inadequate. Dosage 
adjustments are not required for elderly patients or those with renal impairment. 
1.7 Orlistat 
Orlistat is a nonsystemically acting gastric and pancreatic lipase inhibitor that 
limits the absorption of dietary fat. It is a highly lipophilic hydrogenated derivative 
oflipastatin, a natural product of Streptomyces toxytricini (Figure 1.3). 
O Q H o o 
Figure 1.3: Chemical Structure of Orlistat 
Page 27 
Chapter 1 , , ^ Introduction 
1.7.1 Mode Of Action 
Orlistat exerts its therapeutic effect in the lumen of the stomach and small 
intestine. It partially prevents the hydrolysis of triacylglycerol (dietary fat) by 
inhibiting gastric and pancreatic lipases through the formation of a covalent bond 
with the active serine residue site of these enzymes. Consequently, by limiting the 
production of absorbable free fatty acids and monoacylglycerols, orlistat indirectly 
inhibits the absorption of dietary fat (Guerciolini R, 1997). Administration of orlistat 
120mg with a liquid fat meal significantly reduced postpranial pancreatic lipase 
activity (p < 0.03) in the small intestine by approximately 75% by compared to 
placebo (Borovicka J et al 2000). 
1.7.2 Adverse events and current status 
The most frequent adverse events associated relate to the gastrointestinal 
system and include oily spotting, flatus with discharge, faecal urgency, fatty/oily 
stools，oily evacuation, increased defecation and faecal incontinence. The 
recommended dosage is 120 mg taken immediately before, during or up to one hour 
after each main meal. If a meal is missed or contains no fat, the dose should be 
omitted. 
Orlistat is indicated in conjunction with a mildly hypocaloric diet in the 
treatment of obese patients with a BMI of 30 kg/m^ or overweight patients (BMI of 
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- 2 8 kg/m^) and with associated risk factors such as hypertension, diabetes or 
dyslipidaemia (Lucas KH et al 2001). Treatment with orlistat should only be started 
if diet alone has previously produced a weight loss of at least 2.5 kg over a period of 
4 consecutive weeks. Treatment with orlistat should be discontinued after 12 weeks 
if patients have been unable to lose at least 5% of their body weight as measured at 
the start of drug therapy (F. Hoffmann-La Roche Ltd, Prescribing information, 2001). 
1.7.3 Therapeutic Potential in the Metabolic Syndrome 
As discussed earlier, obesity is a well recognised risk factor for type 2 
diabetes and the primary treatment for type 2 diabetes is weight loss. With orlistat's 
unique inhibitory mode of action on the absorption of dietary fat, thereby indirectly 
promoting weight loss, it has a therapeutic potential in the treatment of the various 
aspects of the metabolic syndrome. 
Orlistat use was associated with significantly improved LDL-cholesterol, total 
cholesterol and triglycerides. The cardiovascular risk was reduced due to a reduction 
in the systolic and diastolic blood pressure in addition to the lipid improvements 
(Hollander PA et al 1998, Hauptman J et al 2000. Rossner S et al 2000). Weight loss 
will also results in improved blood glucose, decreased fasting insulin concentrations 
and therefore, reducing insulin resistance. 
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1.8 Study Hypothesis 
In view of the above mentioned pharmacology of orlistat and rosiglitazone, 
their use in insulin resistant patients may prove beneficial. Therefore, it was 
postulated that both agents, used independently, should produce some improvements 
in some, if not all of the parameters, of the metabolic syndrome. 
1.9 Study Objectives 
The aims of the study were : 
1. to examine the effects of orlistat and rosiglitazone, in a group of Chinese 
patients affected by the metabolic syndrome 
2. to assess the changes of cardiovascular risk factors in each groups of patients 
and 





Chapter 2 Research Design and Methods 
2 Study Protocol 
This study was performed in accordance with the protocol as approved by the 
Ethics Committee of the Chinese University of Hong Kong, and in accordance with 
the revised Declaration of Helsinki (1983) governing experimentation with human 
volunteers. Patients were recruited from the Diabetes clinic of in the Prince of Wales 
Hospital (PWH) and all subjects gave written informed consent prior to participation. 
An example of the consent form is shown in Appendix I. 
2.1 Overall Design 
The study consists of a prospective, single-blinded, randomised and placebo-
controlled clinical trial, which last for six months. The overall study design is shown 
in Table 2.1. All assessments were completed by the same members involved 
throughout the study (i.e. physician, certified research nurse and research student). 
2.1.1 Patients Selection Criteria 
2.1.1.1 Inclusion Criteria 
Subjects of either gender between 18 to 75 years old of age and are 














































































































































































































































































































































































































































Chapter 2 Research Design and Methods 
impaired glucose tolerance after repeated OGTT or type 2 diabetes mellitus with 
glucose intolerance controlled by diet or by only one oral hypoglycaemic agent was 
recruited. The criteria for IGT have been defined earlier by the American Diabetes 
Association (Table 1.2). Female patients of childbearing potential are eligible to 
enter and participate in the study if they have a negative urine pregnancy test prior to 
enrolment and they will practice an acceptable method of birth control during the 
period of study. Patients will also be assessed on their willingness and ability to 
comply with the study protocol, for example on the completion of provided diary 
cards and study drug administration, before being recruited into the trial. 
2.1.1.2 Exclusion Criteria 
Female subjects who are pregnant or breast-feeding or planning a pregnancy 
during the course of the study or who are of child-bearing potential and not using an 
accepted method of birth control were excluded from the study. This is because the 
effect of study medications on pregnancy is unknown. Also excluded are patients on 
insulin or more than one oral hypoglycaemic agents, patients taking appetite 
suppressant drugs on a regular basis (including herbals and nutritional supplements 
for weight loss or control purposes) and patients with known hypersensitivity to any 
of the study medications. Other exclusion conditions included documented coronary 
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artery disease or pancreatic disease; any history or presence of cancer, psychiatric or 
neurological disorders requiring chronic medications that may influence compliance 
of study medication; history of alcohol or substance abuse, and impaired hepatic or 
renal function (AST, ALT >1.5 times the upper limit of normal, serum creatinine 
>115 |imol/L). In addition, patients that are currently enrolled or have participated in 
other clinical trials within 30 days prior to the screening visit are not eligible for the 
study. 
2.1.2 Recruitment Period 
2.1.2.1 Screening Period 
Patients were screened for eligibility according to the inclusion and exclusion 
criteria described earlier during their regular visit to the Prince of Wales Hospital 
Diabetes Specialty Clinic. If the patient met the entry criteria and had agreed to 
participate in the study, he would be referred to the certified research nurse, who 
would then give a full verbal and written explanation of the study protocol 
(Appendix II). Visit 1 appointment was then given to the patient at the Clinical 
Pharmacology Studies Unit and the patient referred to a dietitian for assessment of 
his daily energy requirement. A balanced hypocaloric diet, targeting an energy deficit 
of 500 kcal to 800 kcal below enrollment weight maintenance requirements, was 
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provided to each of the subjects. The subjects were then counseled to maintain the 
hypocaloric diet and usual exercise regimen (at least a 30 minute aerobic exercise 
daily) during the run-in period and study period. 
2.1.2.2 Run- In Period (Visit 0) 
During Visit 0’ a consent form in Chinese (Appendix I) was then given to the 
patient to be signed. Subjects then undergo routine investigations as detailed in Table 
2.1 and their full medical or surgical history taken. 
Medications in the form of capsules, were packed into three different 
containers, each labeled for breakfast, lunch or dinner. Patients were instructed to 
take a capsule immediately before or after each main meal as according to the 
containers. Should the patient forget to take the study medication and it is past an 
hour after the meal, patients were told to forgo that dose and indicate the reason in 
the medication diary. During this run-in period, a 4-weeks supply of placebo was 
given and patients who demonstrated to have at least 70% compliance with the 
placebo during the run-in period will enter the randomised treatment period. Patients 
were instructed to bring all study medications (including empty bottles) to each study 
visit and appointment for Visit 1 was made. 
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2.1.2.3 Randomisation 
At the end of the initial assessment period at Visit 0，a pill-count and 
medication diary was used to assess the compliance of patients and incidence of 
adverse events. Non-compliance is defined as study medication consumption of less 
than 70%. Following review of the laboratory results, those compliant subjects who 
still fulfilled the inclusion criteria then undergo physical examination by the 
physician and details of prior and concomitant medications were recorded. A 
standard 75 g OGTT was given with blood samples drawn on 0 minute, 30 minute, 
60 minute and 120 minute for plasma glucose and insulin levels. An ultrasound 
examination of the wall thickness of the left and right common carotid arteries was 
performed. The clinical record form (CRF) was completed (Appendix III) and 
patients were randomized to one of the three treatment groups and the relevant study 
medications dispensed. Details regarding the taking of medications and adherence to 
lifestyle modifications were emphasized again. 
In the orlistat group, patients were randomized to receive 120 mg of orlistat 
three times daily. For the rosiglitazone group, patients were given 2 mg of 
rosiglitazone in the morning and evening doses, the afternoon dose was substituted 
with lactose-filled placebo. The placebo group patients received placebo for all the 
three doses. Hence, all patients received three different bottles of medications, each 
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bottle with instructions labeled to take the medications after breakfast, lunch or 
dinner respectively. Patients were instructed not to mix the contents of any bottles 
and to bring back each container as it is during the next visit. 
2.1.2.4 Evaluation Periods (Visit 2 to 4) 
Following randomization to either of the three groups, all patients were 
reviewed for adverse events and routine investigations were conducted during each 
follow-up (Table 2.1). At the end of the study (Visit 4)，an ultrasound examination of 
the wall thickness of the left and right common carotid arteries and a standard 75g 
OGTT were conducted again. The subjects were then encouraged to continue to 
maintain the hypocaloric diet even after the study has completed. 
2.2 Investigations 
Baseline investigations included fasting plasma glucose, glycosylated 
haemoglobin (HblAc), lipid profiles (total cholesterol, triglycerides, LDL-
cholesterol and HDL-cholesterol), renal function tests, liver functions and complete 
blood count. These laboratory tests were performed by the Department of Chemical 
Pathology at the Prince of Wales Hospital. Blood pressure and anthropometric 
parameters were also recorded. Additional investigations conducted at Visit 1 and 
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Visit 4 included a standard 75g OGTT and an ultrasound of the wall thickness of the 
left and right common carotid arteries conducted by the Department of Radiology, 
Prince of Wales Hospital. Patients were instructed not to take any medications 
(including oral anti-diabetic medications) prior to OGTT. 
2.2.1 Oral Glucose Tolerance Test (OGTT) 
The oral glucose test was developed by Yalow and Berson in 1960 (Yalow et 
al.，1960). It is the most commonly used method to evaluate whole body glucose 
tolerance in vivo. The procedure involves the measurement of plasma glucose and 
insulin at the 0-minute, 30-minute, 60-minute and 120-minute intervals following a 
standard 75g glucose load. It is general practice that plasma insulin levels of the 
corresponding plasma glucose values are also measured as they can provide 
additional information. Methods of assessment include calculating the plasma 
glucose to plasma insulin ratio (Yalow et al 1960)，and more often, calculating the 
areas-under-the-curve (AUG) of the glucose and insulin concentrations versus time 
curves. 
2.2.2 Anthropometric measurements 
Recruited patients would be weight and his height measured for the 
determination of the BMI, which was calculated from the subject's weight and height 
using the formula: 
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BMI= Weight (kg) 
Height ' (m” 
A skin-caliper (Skyndex Electronic Body Fat Calculator, Justic & Co.，Inc., 
AR，U.S.A) was used to assess the body fat. The biceps, triceps, subscapular and 
iliac areas were selected for measurement. Skinfold thickness measurement was 
obtained by pinching the skin and adjacent subcutaneous tissue between the thumb 
and forefinger, pulling it away from the body just far enough to allow the jaws of the 
caliper to impinge on the skin. The readings were repeated three times to improve 
accuracy and reproducibility of the measurements. The data were automatically 
recorded by the caliper and processed by a built-in calculator according to the 
formula developed by Dumin and Womersley (Dumin et al.’ 1974): 
495 %Fat = — — — 450 BodyDensity 
where body density is estimated using skinfold data obtained from specific parts of 
the human body. 
2.3 Analytical Methods 
2.3.1 Determinations of insulin levels in plasma samples 
Insulin levels in plasma samples were determined using the DAKO Insulin kit 
(DakoCytomation Ltd., 2002). The standard assay procedure and the technical 
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precautions are as described in the user's manual. Blood samples are collected in 5-
mL specimen tubes containing heparin. Samples are centrifliged immediately at 3000 
rpm for 10 minutes (Accuspin FR, Beckman, Califonia, U.S.A.) to separate plasma 
from blood cells. The separated plasma is then stored at -20 for up to 28 days. 
2.3.1.1 Principle of the insulin assay 
Dako insulin is an enzyme linked immunosorbent assay (ELISA) for the 
quantitative measurement of insulin in human serum and plasma. It is based on two 
monoclonal antibodies. A complex is formed with the simultaneous incubation of 
samples and enzyme-labelled antibody in a microplate well coated with a specific 
anti-insulin antibody. The unbound enzyme-labelled antibody is then removed by a 
simple washing step. The bound conjugate is detected by reaction with the substrate 
3,3 ',5,5'-tetramethylbenzidine. The reaction is stopped by adding acid, resulting in a 
colorimetric endpoint that is read spectrophotometrically at 450 nm. The assay 
includes a set of calibrators of known insulin concentration where a calibration curve 
was constructed (Figure 2.1). The level of insulin in patient samples is then 
calculated from the calibration curve. The assay principle is shown in Figure 2.2. The 
intra-assay precision had a coefficient of variation in the range of 5.1 - 7.5% and the 
coefficient of variation for inter-assay precision was 4.2 - 9.3% (DAKO Diagnostic 
Ltd., 2002). 
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Figure 2.1. Calibration curve 
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2.3.2 Determination of glucose concentrations in samples 
Blood Samples were collected in fluoride-containing specimen tubes and 
centriflige within 30 minutes of collection. The glucose concentration in the 
separated plasma is then measured using the Gluco-quant ® Glucose (HK) Reagent 
(Roche Diagnostics GmbH, Manneim) employed in a COBAS ® MIRA analyzer (F. 
Hoffman-La Roche co. Ltd., Basle, Switzerland). The test range is from 0.11 mmol/L 
to 41.60 mmol/L. The inter-assay coefficient of variation was 0.8%. 
2.3.2.1 Principle of the glucose assay 
The hexokinase method (Schmidt 1961，Peterson & Young 1958) is a 
recognized reference method. The reaction is started when the sample is added to the 
working reagent (buffer/ATP/NADP/Hexokinase/G-6PDH): 
glucose + ATP hexokinase�。一 6 — P + ADP 
Hexokinase catalyses the phosphorylation of glucose to glucose-6-phosphate by ATP. 
G - 6 - P D H G - 6 - P + NADP+ > g l u c o n a t e - 6 - P + NADPH + H+ 
Glucose-6-phosphate dehydrogenase oxidizes gIucose-6-phosphate in the presence of 
NADP to gIuconate-6-phosphate. No other carbohydrate is oxidized. The rate of 
NADPH formation during the reaction is directly proportional to the glucose 
concentration and can be measured photometrically at 340nm. 
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2.4 Calculations 
2.4.1 Insulin (hepatic) sensitivity (HOMA) 
Many attempts have been made to assess insulin sensitivity from OGTT. 
Matthews and colleagues proposed the homeostatic model assessment (HOMA) to 
provide equations for estimating insulin resistance (HOMA-IR) and p-cell function 
(HOMA estimate of P-cell) from simultaneous fasting measures of insulin and 
glucose levels. These authors found that the HOMA-based insulin resistance 
(HOMA-IR) score was strongly correlated with insulin sensitivity assessed by the 
glucose clamp technique in both non-diabetic and diabetic subjects (r = - 0.83 and -
0.92’ respectively. This approach, which relies on the product of fasting plasma 
glucose (FPG) and fasting plasma insulin (FPI) concentrations, has been evaluated in 
several publications (Philips D et al 1994’ Bonora E et al 2000). In this study, 
HOMA refers to HOMA-IR, and it was calculated with the formula : 
[Fasting plasma insulin (|aU/mL) x Fasting plasma glucose (mmol/L)] / 22.5 
With such a method, high HOMA scores denote low insulin sensitivity 
(insulin resistance). The CVs of HOMA scores as validated by Bonora E and 
coworkers were 9.4 士 0.7 and 7.8 土 0.6% respectively, in 20 non-diabetic subjects 
and 20 diabetic individuals. 
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2.4.2 Area Under the Curves 
According to Walker EA, 1994，the measure for area under the curve is used 
when an integrated assessment is more useful in understanding a phenomenon. In the 
OGTT tests, the integrated expression of glucose and insulin levels over time may 
give the best assessments of the degree of increase in glucose or insulin levels. The 
area under the curve is a useful summary approach as it allows the use of standard 
methods to analysis repeated measures (Matthews JNS et al 1990). The product of 
the glucose area under the plasma glucose curve and insulin area under the plasma 
insulin curve is calculated using the trapezium rule. This rule involves the addition of 
the areas under the graph between each pair of consecutive observations. At 
measurements yl and y2 at times tl and t2, the area under the curve between those 
two times is the product of the time difference and the average of the two 
measurements. Thus, we get 
(/2-/1)0；1 +少 2) 
2 
The trapezium rule can be summarized as follows: 
肌 c =这(/,.+,-0(儿+兄>1) ^ i=0 
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2.4.3 Sample Size Calculations 
The equation used to calculate sample size is : 
— (办 
where Za = 1.96, d is the mean difference that was observed, s^  is the variance. In 
order to reduce the effect of beta error due to small sample size, a beta error of 20% 
(one-tailed test), which correspond to Zp of 0.84 is used in addition to the alpha 
error. Therefore, the equation for sample size calculation used for this study is : 
一 (df 
The desired statistical power is 0.95. 
Considering the effects of orlistat and rosiglitazone on fasting serum glucose and 
insulin levels in the previous studies: 
The mean FPG of orlistat-treated patients was reduced from baseline by 0.42 士 0.05 
mmol/L (Heymsfield et al 2000). The sample size needed to achieve a 95% 
confidence interval of 土 0.05 is (1.96 + 0.84)2 x 2 x (0.05)2 丨 0052 = 15.68. 
The mean fasting serum insulin of orlistat-treated patients was reduced from baseline 
by 14 ± 7 pmol/L (Heymsfield et al 2000). The sample size needed to achieve a 95% 
confidence interval of 土 10 is (1.96 + 0.84)2 乂 2 x {if / 10^ = 7.68. Based on the 
above estimations, the orlistat group should have a minimum of 16 patients. 
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The mean FPG of rosiglitazone-treated patients was reduced by 0.9 土 2.1 mmol/L 
(Nolan JJ et al 2000) in the 4-mg rosiglitazone group. The sample size needed to 
achieve a 95% confidence interval of 土 2 is (1.96 + 0.84)2 x 2 x (2.21)2! ^^ = y^g 
Considering the 4mg rosiglitazone group, the mean insulin of rosiglitazone-treated 
patients was reduced from baseline by 21 ± 3 9 pmol/L (Nolan JJ et al 2000). The 
sample size needed to achieve a 95% confidence interval of 土 40 is (1.96 + 0.84)2 乂 2 
X (39)2 / 4o2 = 14.9 The rosiglitazone group should have a minimum of 15 patients. 
To make any comparisons meaningful in this study, it is decided that at least 16 
patients should be included in each study group. 
2.5 Statistical Analysis 
All statistical analyses were performed using Microsoft Excel and Statistical 
Package for Social Sciences for Windows version 11.5 (SPSS, Inc.). Distributions 
were tested for normality using the Shapiro-Wilk W test. One-way analysis of 
variance (ANOVA) was used to determine if the subjects in all three groups were 
comparable at entry. For data not following a normal distribution, their comparability 
at entry were validated using a non-parametric test (Kruskal-Wallis Test). 
Using laboratory data as a dependent variable, a repeated measurement 
analysis of variable (ANOVA) was performed to test for differences between the 
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three groups and between visits. To compare the different treatments with the control, 
the one-way ANOVA with the post hoc, Dunnett t (2-sided) test, was conducted on 
the percentage differences of the pre- and post-treatment of parameters. The results 
were expressed as mean 土 SD. Non-normally distributed data were logarithmically 
transformed to approximate a linear distribution. Data not following a normal 
distribution even after transformation were validated using a non-parametric test 
(Kruskal-Wallis Test). Mann-Whitney U test was also used to compare the effects of 
different treatments with the control group. 
Graphs were plotted using Microsoft Excel 2000 for Windows. A p-value < 




Chapter 3 Results 
3.1. Study Population 
A total of 90 potential Chinese patients age > 20 years were screened but only 63 
patients with persistent fasting plasma glucose > 5.6 mmol/L or OGTT 2h-post 
glucose levels of > 11.1 mmol/L were eligible and randomized into the three 
different study group. Five randomized patients did not complete the study, four of 
them refused participation study in the midst of the trial due to social or personal 
reasons, the most common reason cited was the inability to comply with the visits. 
The other patient from the control group developed a generalized allergic skin 
reaction to the placebo capsules shortly after randomization and hence, she could not 
complete the study. Therefore，a total of 58 patients were randomized and completed 
the study over the period of six months. The clinical characteristics of these patients 
were described in Table 3.1 with the diagnosis of IGT and type 2 diabetes mellitus 
were defined by ADA (Table 1.3) and the criteria of the metabolic syndrome 
employed was stated by IDF (Table 1.2). A total of 9 patients were on one anti-
diabetic medication, namely metformin, glibenclamide and glipizide. 37 patients 
were classified as having the metabolic syndrome while 29 patients were diagnosed 
as having type 2 diabetes and 20 patients were diagnosed as having IGT. 
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Table 3.1. Clinical characteristics of recruited patients at baseline. 
Orlistat Rosiglitazone Placebo N (%) 
Metabolic syndrome 13 11 13 63.8 
Type 2 DM after OGTT not 11 10 8 50 
on any anti-diabetic agent 
Type 2 DM taking one anti- 3 4 2 15.5 
diabetic agent 
IGT not on any anti-diabetic 5 6 9 34.5 
agent 
Definition of the metabolic syndrome was defined by IDF (Table 1.2) and type 2 diabetes mellitus and 
IGT were defined by ADA 2004 (Table 1.3) 
3.2. Randomization 
19 patients were randomized to receive orlistat therapy, 20 patients were in 
the rosiglitazone group，and 19 patients recruited in the control group. Comparison of 
the baseline characteristics of the randomized subjects is summarized in Table 3.2, 
3.3, and 3.4. In general, subjects randomized to the rosiglitazone group were slightly 
lighter (body weight 69.9 土 12.5 kg) and shorter (body height 156.5 土 7.6 cm) with a 
higher HblAc and FPG. The orlistat group has the highest total cholesterol levels 
and HOMA score amongst the three groups. The control group has a higher systolic 
and diastolic blood pressure and a lower FPG. Interesting, the 75g OGTT 2 hour 
glucose and GlucoseAUC for the control group were also less than the active treatment 
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groups. However, these differences were not statistically significant. The only 
significant difference found at baseline is the lower triglyceride levels in the control 
group. 
3.3. STUDY RESULTS 
The clinical characteristics of the patients were summarized in Table 3.5. At baseline, 
no patients were classified as normoglycaemia after 75g-OGTT. However, at the end 
of the six months treatment, a total of 11 patients became normoglycaemic, with 6 of 
them belonging to the rosiglitazone group. Also, the number of patients who were 
type 2 diabetes after OGTT increased while those who became IGT decreased in all 
three groups. Surprisingly, while the number of patients who were diagnosed with 
the metabolic syndrome decreased in the orlistat group, the figures increased in the 


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Chapter 3 Results 
Table 3.5. Clinical characteristics of recruited patients at the end of therapy. 
Orlistat Rosiglitazone Placebo N (%) 
Metabolic syndrome 9 14 15 65.5 
Type 2 DM after OGTT not on 7 4 9 34.5 
any anti-diabetic agent 
Type 2 DM taking one anti- 3 4 2 15.5 
diabetic agent 
IGT not on any anti-diabetic 8 6 4 31 
agent 
Normoglycaemia 1 6 4 19 
Definition of the metabolic syndrome was defined by IDF (Table 1.2) and type 2 diabetes mellitus 
and IGT were defined by ADA 2004 (Table 1.3) 
3.3.1. Indices of Glycaemic Control 
3.3.1.1. H b A l c 
There is no statistically significant difference when comparing the effects of 
drug treatments on HbAlc . As shown in the time plot (Figure 3.1), the control group 
has almost no change in the HbAlc levels at the end of the treatment. However, 
when compared with control, rosiglitazone has the most reduction in HbAlc with a 
mean difference of -0.2044 士 0.25 mmol/L (p = 0.64), whereas orlistat has a mean 
difference of 0.111 土 0.24 mmol/L (p = 0.86). Interestingly, both the rosiglitazone 
and orlistat group showed maximum reduction in HbAlc after 3 months of treatment, 
























































































































































































































































































































































































































































































































































































































































































































Chapter 3 Results 
Figure 3.1: HbAic 
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Figure 3.2: Mean Fasting Plasma Glucose 
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3.3.1.2. Fasting Plasma Glucose 
There is a significant treatment effect, indicating that the treatments do 
reduce the fasting plasma glucose over time (p = 0.01). However, there is no 
statistically significant difference (p = 0.903) between the treatment groups, with the 
control group showing almost no difference after treatment (Figure 3.2). When 
compared with control, rosiglitazone group has a mean difference o f-0.109 土 0.25 
mmol/L while orlistat group has -0.087 土 0.25 mmol/L. As for HbAic, the time plot 
for FPG (Figure 3.2) showed a great reduction just after the start of treatment, after 
which there is a rebound increase. 
3.3.1.3. Fasting Insulin 
Figure 3.3 showed an interesting trend, with the orlistat group displaying a 
slight reduction in fasting insulin. However, there is a slight increase for the control 
group while the rosiglitazone group had a drop in the fasting plasma insulin value. 
There is a statistically significant difference amongst the groups in the percentage 
differences pre- and post-treatments (p = 0.006). When comparing the two treatment 
groups with the control, the orlistat group has a mean plasma insulin difference of -
11.82 士 5.6 pmol/L (p = 0.07) while the rosiglitazone group i s - 18.11 ±5 .6 pmol/L 
(p = 0.004)，indicating significant improvements. 
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Figure 3.3: Fasting Plasma Insulin 
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3.3.1.4. 75g Oral Glucose Tolerance Test 
3.3.1.4.1. Glucose 
The time plot (Figures 3.4, 3.5 and 3.6) for insulin levels after 75g OGTT 
showed that the plasma glucose levels during OGTT for the three groups were just 
comparable at baseline (p = 0.058). However, after six months of treatment, there is 
no apparent difference in the plasma glucose between the groups (p 二 0.539). 
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Figure 3.4: Mean Plasma Glucose Levels after OGTT for Orlistat 
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Figure 3.5: Mean Plasma Glucose Levels after OGTT for Rosiglitazone 
~ ~ • B a s e l i n e - - » - - End of Therapy 
苦 20.0 r  
^ 18.0 T 
^ 16.0 - 1 X 
b二： ~ { 
10.0 4 1 
E 4.0 -
n 2.0 
I 0.0 ： , 
0 30 60 90 120 150 
Time after OGTT (min) 
(Vertical bars represent SD. Points are staggered for display purposes) 
Figure 3.6: Mean Plasma Glucose Levels after OGTT for Placebo 
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3.3.1.4.1.1. 2-hr Glucose 
When comparing the effects of drug treatments, there is no statistically significant 
difference. Surprisingly, when the percentage differences in mean 2-hr glucose pre-
and post- treatments were compared, the different groups gave no statistically 
significant result (p = 0.057) as well. Within groups, both the control and the orlistat 
groups had almost no change. However, the rosiglitazone group had a drop (p = 
0.10), indicating some improvement in the 2-hr glucose value. 
Figure 3.7: 75g OGTT - 2-hr Glucose 
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3.3.1.4.1.2. Glucose AUC 
Similarly, although all three groups showed a decrease in the mean glucoscAuc 
values, there is no statistically significant result within and amongst groups. 
Comparing the percentage differences in mean glucoscAuc before and after 
treatments of the three groups gave no statistically significant result (受=0.570 , p 
0 . 7 5 2 ) . 
Figure 3 . 8 : 75g O G T T - GIUCOSCAUC 
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3.3.1.4.2. Insulin 
The time plot (Figures 3.9, 3.10 and 3.11) for insulin levels after 75g OGTT 
showed no statistical difference in the three groups at baseline. However, after six 
months of therapy, for the rosiglitazone group, there is an obvious reduction in the 
plasma insulin levels when compared with the control (p < 0.0005). In contrast, 
orlistat showed no obvious difference in the plasma insulin levels (p = 0.831). 
3.3.1.4.2.1. 2-hr Insulin 
There is a statistically significant difference between treatment groups (p = 
0.002) as shown in Figure 3.12, with the orlistat group displaying an almost 
comparable trend to the control (p = 0.98). In contrast, the rosiglitazone group 
displayed a significant treatment effect (p = 0.004). Within groups, there is no 
significant pre- and post-treatment difference for the control and orlistat groups, 
except for the rosiglitazone group (p = 0.006). 
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Figure 3.9: Mean Insulin after OGTT for Orlistat 
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Figure 3.10: Mean Insulin after OGTT for Rosiglitazone 
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Figure 3.11: Mean Insulin after OGTT for Placebo 
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Figure 3.12: 75g OGTT - 2-hr Plasma Insulin 
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3.3.1.4.2.2. Insulin AUC 
From Figure 3.13, while the orlistat group was comparable to the control (p 
=1 .00) , the rosiglitazone group showed a dramatic reduction in the mean insulinAuc 
value, with a statistically significant difference when compared with control (p = 
0.016). The percentage differences pre- and post treatments were also statistically 
significant (p = 0.005). Within groups, both the control and orlistat group showed no 
significant difference pre- and post-treatments, but the rosiglitazone group had a 
statistically significant difference (p = 0.001), indicating a great improvement in the 
insulin levels. 
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Figure 3.13 : 75g OGTT - InsuHiUuc 
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Figure 3.14: HOMA Scores 
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3.3.1.5. HOMA Scores 
The interaction between the treatment groups and the change over time was 
statistically significant (p = 0.010). It can be observed from Figure 3.14 that the 
control group has an increase in the mean HOMA score, indicating a worsening of 
insulin resistance. Both the rosiglitazone and orlistat groups showed a decrease in 
mean HOMA score. However, when comparing the percentage differences in mean 
HOMA score before and after treatments between the three groups, there is a 
statistically significant result (义2 = 10.235, p = 0.006). When comparing with the 
control, both groups displayed significant differences (rosiglitazone group p = 0.005, 
orlistat group p = 0.026). 
Figure 3.14: Percentage Differences for HOMA 
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Chapter 3 Results 
3.3.2. Clinical Determinants 
3.3.2.1. Lipid Profiles 
3.3.2.1.1. Total Cholesterol 
There is statistically significant difference when comparing the effects of drug 
treatments on total cholesterol (p = 0.001). However, when compared to the control 
group, both the rosiglitazone and orlistat groups had no significant difference (p = 
0.090 and 0.091 respectively). In contrast, when comparing within the groups itself, 
the orlistat group had a significant improvement (p-value < 0.0005) from baseline, 
while there is no statistical difference for the control and rosiglitazone groups. 
Figure 3.16: Total Cholesterol 
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3.3.2.1.2. HDL-Cholesterol 
Although there is a statistically significant treatment effect, indicating a difference 
between therapies on HDL-cholesterol levels (p = 0.038)，but when compared to the 
control, both the rosiglitazone and orlistat groups displayed no statistically 
significant difference (p = 0.88 and 0.09 respectively). In addition, comparing within 
groups showed no statistically difference pre- and post-treatments in all three groups. 
Figure 3.17: HDL-cholesterol 
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3.3.2.1.3. LDL-Cholesterol 
There is a statistically significant treatment effect (p = 0.011) on LDL-cholesterol. 
The post hoc tests indicated that the orlistat group is marginally statistically different 
(p = 0.043) while the rosiglitazone group is no difference (p = 0.784) when 
compared to the control group. In contrast, when comparing within the groups itself, 
the orlistat group had a significant improvement (p = 0.002) from baseline, while 
there is no statistical difference for the control and rosiglitazone groups. 
Figure 3.18: LDL-Cholesterol 
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3.3.2.1.4. Triglycerides 
From Figure 3.19, although the baseline triglycerides for the three groups were not 
comparable at entry, their endpoints were almost comparable despite the fact that the 
placebo group had a much lower triglyceride level to start with. The control groups 
showed an increase from baseline while the other two groups had a reduction. The 
effects of drug treatments on triglycerides were statistically different amongst the 
three groups (p = 0.02). When compared to the control, both the rosiglitazone and 
orlistat groups displayed statistically significant difference (p = 0.037 and 0.022 
respectively). 
Figure 3.19: Triglycerides 
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Chapter 3 Results 
3.3.2.2. Anthropometric Evaluations 
3.3.2.2.1. Body Weight 
It is shown in Figure 3.20 that there is a mean weight loss in the orlistat 
group but for the rosiglitazone group, there is a mean weight gain instead. There 
is a statistically significant difference between the groups (p = 0.001) on the 
weight differences. When comparing with the control, the orlistat group had a 
mean weight loss of -0.739 土 0.33 kg (p = 0.050) while the rosiglitazone group 
has a mean weight gain of 1.064 土 0.33 (p = 0.003). 
Table 3.9 : Weight Gain at 1,3 and 6 month 
are expressed as changes in kg of the body weight when compared with 
baseline 
Weight Changes Orlistat Rosiglitazone Control P-value 
( K g ) Mean + SD Mean + SD Mean + SD 
(Range) (Range) (Range) 
1 Month -0.54 土 0.9 0.13 ± 1.2 -0.52 ± 1.4 ^ 
( -1 .9-1 .2) ( -3 .0-2.0) ( -3 .8- 1.2) 
3 month -1.02 ± 1.5 -2.5 ± 1.5 -0.54 ±2.0 ~ 
( -4 .0-1 .6) (-2.5 - 4.0) ( -5 .8-3.0) 
6 month -2.12 ± 1.9 0.73 土 2.5 -0.41 ±2.2 o ! ^ ^ 
(-6.5 - 1.4) (-5.0 - 5.4) (-6.3 - 3.2) 
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Figure 3.20: Mean Weight Differences 
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Figure 3.21: Mean Waist Differences 
- - • - - Orlistat — — Rosiglitazone ~ A “ Placebo 
4.0 1 
3.0 T T J 
I 2.0 - T T 
w -p 
8 10 丁 
§ 0.0 Ik- 
. i - 1 0 、 ： ： ^ ^ ！ ^ ： ^ ^ 丨 ; ^ ： ! ! ! ： ： ^ ^ ™ ™ -w .2 0-i .. "M 
> -3.0 -
to 丄 
^ -4.0 . . 
-5.0 _[ 
-6.0 1 , , , , , 
0 1 2 3 4 5 6 7 
Months of Therapy 
(Vertical bars represent SD. Points are staggered for display purposes) 
Page 75 
Chapter 3 Results 
3.3.2.2.2. Waist Circumference Difference 
Figure 3.21 showed that orlistat displayed a steady decrease in waist 
circumference while rosiglitazone had an increase since the start of therapy. 
When comparing between treatments, the percentage differences in waist pre-
and post- treatments just reached a statistically significant result (p = 0.049). In 
contrast，when compared to the control, orlistat produced a net reduction of -
0.702 土 0.59 cm (p = 0.041) and rosiglitazone showed almost no difference with 
a mean reduction of -0.090 土 0.59 cm (p = 0.746). 
3.3.2.2.3. Hip 
There is a statistically significant difference between groups on the 
percentage differences in hip pre- and post-treatment (p = 0.002). From Figure 
3.22, there is almost no change in the control group on the hip difference 
throughout the study. In contrast, when compared to the control, rosiglitazone 
had an increase of 0.755 土 0.50 cm (p = 0.16) and orlistat had a decrease o f -
0.658 ±0.50 cm (p = 0.243). 
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Figure 3.22: Mean Hip Differences 
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Figure 3.23: Body Fat Differences 
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3.3.2.2.4. Body Fat 
Both the control and rosiglitazone group have a net increase in the mean 
body fat differences at the end of treatment while the orlistat group had a net 
decrease (Figure 3.23). When comparing between groups on the percentage 
difference in body fat before and after treatment, a statistically significant result 
of = 10.28, p = 0.006 is obtained. In contrast to control, orlistat has a 
significant mean difference of -1.03 士 0.42 % (U = 89.0, p = 0.008) and 
rosiglitazone showed almost no difference (U= 180.0, p = 0.779). 
3.3.2.2.5. BMI 
When comparing between groups on the percentage differences pre- and 
post-treatments, there is a statistically significant difference of 14.60, p = 
0.001. Figure 3.24 shows that the control group has almost no change in the BMI 
values at the end of the treatment while orlistat had a reduction with a mean BMI 
difference of -0.270 土 0.07 kg/ml Rosiglitazone has a slight increase, resulting 
in a mean BMI difference of 0.103 士 0.07 kg/ml Interestingly, both the orlistat 
and rosiglitazone groups displayed maximum reduction in the first three months, 
after which there is a rebound increase, explaining why the differences in BMI is 
not as dramatic as expected. But when comparing with the control, orlistat 
produce a significant p = 0.008 while for rosiglitazone p = 0.087. 
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Figure 3.24: BMI Differences 
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3.3.2.3. Blood Pressure 
As shown in table 3.10，there are no statistically significant differences 
for both the mean systolic and diastolic blood pressure before and after treatment 
in all the three groups. 
3.3.2.4. RCCA and LCCA 
Tables 3.11 showed that there are no statistically significant differences 
in the wall thickness of both the right and left carotid arteries before and after 





















































































































































































































































































































































































































































































































































































Chapter 3 Results 
3.3.2.5. Other outstanding measurements 
There are a number of other outstanding results from this study that is 
outside the scope of this thesis. These included the assessment of visceral obesity 
by magnetic resonance imaging (MRI) and metabolic cart. Results were not 
available at the time of writing, but the inclusion of these results would make this 
study more meaningful and significant. 
3.4. Side Effects experienced 
All the patients on orlistat had the typical gastrointestinal adverse effects 
such as oily stools and increased defaecation. Other common side effects 
observed in all three groups included skin rash (about 0.5%) and dizziness. The 
rosiglitazone and control groups also had other gastrointestinal adverse effects 
(lo/o) such as flatulence and other gastrointestinal disturbances (diarrhoea, 
constipation and nausea). Most side effects resolved as the treatment progressed, 






Chapter 4 Discussion & Conclusion 
4.1. Summary of the results 
The main aim of the study was to determine whether orlistat and rosiglitazone 
improved the metabolic environment of Chinese patients affected by the metabolic 
syndrome. All recruited patients exhibited some or all of the characteristics of the 
metabolic syndrome, which included glucose intolerance, android obesity, 
hypertension, dyslipidaemia, hyperinsulinaemia and insulin resistance. The efficacy 
and side effects of orlistat and rosiglitazone were evaluated in 63 Hong Kong 
Chinese subjects recruited at the Prince of Wales Hospital. Similarities of baseline 
characteristics of subjects between groups (Table 3.1 to 3.3) indicated that the 
comparisons made between the groups following treatment are valid. 
4.1.1 Effects of Diet and Lifestyle Changes 
In general, although patients in the control group had little or no changes in 
the major glycaemic indices, cholesterol, weight and android obesity, there is still 
some degree of deterioration in their insulin resistance status, as reflected in the 
increasing fasting insulin levels, HOMA scores, triglycerides, LDL-cholesterol, hip 
and body fat levels. This is consistent with the metabolic changes associated with the 
metabolic syndrome as described in Table 1.1. 
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There is also a thickening of the carotid arteries, possibly due to insulin 
resistance. Although statistically insignificant, there is a 21% increase in thickness at 
the mid left carotid artery and a 17% increase at the distal right carotid artery. 
4.1.2 Effects of Orlistat 
In contrast, patients on orlistat demonstrated improved serum lipid, especially 
on the reduction of total cholesterol (12.1%) and LDL-cholesterol (20.9%), as 
anticipated from orlistat's inhibitory effect on the absorption of dietary fat. Although 
orlistat does not produce any statistically significant improvements in the HDL-
cholesterol (0.5% drop) nor triglycerides (4% reduction) levels, this finding is 
consistent with clinical studies (Hollander PA et al., 1998 and Torgerson JS et al., 
2004). Interestingly, the orlistat group was almost comparable with the control group 
on the percentage difference of pre- and post-treatments for the fasting insulin (Table 
3.4). However, after 75g-OGTT, there is a slight improvement in the 2-hr insulin and 
insuliriAuc, indicating some improvement in insulin resistance. 
The changes for the orlistat group are most apparent after 3 months of therapy 
(HbAic, total cholesterol, triglycerides and BMI). Improvements in the 
anthropometric parameters (weight changes, waist and hip differences and body fat 
differences) are most apparent after 6 months of treatment. 
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Weight loss has been reported to improve glucose tolerance, increase insulin 
sensitivity and improve lipid profiles. However, in this study, improvements in the 
anthropometric evaluations did not produce any significant changes in the glycaemic 
indices for the orlistat group, except for a mild reduction in the glycaemic indices 
and HOMA scores. This may be due to the fact that most clinical trials were 
conducted over a period of at least one year, with a large sample size. Hence, the 
effects of orlistat on the glycaemic indices of blood glucose and insulin levels may 
not be apparent in this study, which was limited by the comparatively small sample 
size and a short duration of therapy. 
4.1.3 Effects of Rosiglitazone 
The rosiglitazone group, in comparison, exhibits maximum improvements in 
the glycaemic indices and HOMA scores, which is consistent with rosiglitazone's 
role as an insulin-sensitiser. Although not statistically significant as compared with 
placebo or orlistat, the rosiglitazone group had a mild increase in the total cholesterol, 
triglycerides, and HDL-cholesterol levels. There is a 12% increase in LDL-
cholesterol, which occurs primarily after 3 months of therapy and remains elevated 
above baseline to the end of therapy. These findings are consistent with other clinical 
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trials involving thiazolinediones, as discussed earlier in Chapter 1 (Thomas JC et al. 
2001 and Khan MA et al 2002.). 
Based on the pharmacological mechanisms of action, rosiglitazone promotes 
increased storage of glucose in cells, resulting in increased weight, hence resulting in 
the modest weight gain, increase in hip circumference and total body fat, as reflected 
in the rosiglitazone group. Rosiglitazone has been found to increase subcutaneous fat 
area but not significantly alter intra-abdominal fat area (SmithKline Beecham 
Pharmaceuticals, Prescribing information 2001), perhaps explaining why there is no 
significant increase in the mean waist difference. 
4.2. Implications for Therapy 
It has been proposed that the metabolic syndrome is a powerful determinant of 
type 2 diabetes and cardiovascular disease (Reaven DM 1988，DeFronzo RA et al 
1991). The features of the metabolic syndrome are observed not only in type 2 
diabetes mellitus and in patients before they develop diabetes, but also in a large 
proportion of individuals with insulin resistance who are relatively euglycaemic and 
who may never develop type 2 diabetes mellitus (Haffher SM, 1990). 
Most metabolic syndrome patients are at a much greater risk for 
atherothrombotic events than are patients who have impaired glucose tolerance or 
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type 2 diabetes mellitus (Lillioja S et al 1993, Martin BC 1992). Cardiovascular risk 
is not increased by hyperglycaemia alone. Instead, it is the accompanying metabolic 
abnormalities combining with hyperglycaemia that impart the high risk for 
cardiovascular atherothrombotic events (Reaven GM 1988). 
4.2.1 Management of metabolic syndrome 
The primary goals of treating metabolic syndrome are prevention of type 2 
diabetes mellitus and cardiovascular events. According to the American Diabetes 
Association and in the NCEP ACEP III report 2001, the management of the 
metabolic syndrome involves reducing underlying causes and treating associated 
nonlipid and lipid risk factors. Treatment must address the multipathologic process 
of metabolic syndrome, with each component identified and aggressively targeted for 
treatment (Table 4.1). Notwithstanding the difficulty and expense of long-term 
prospective intervention, treating individuals with the metabolic syndrome at early 
stages promises to yield real savings in the later financial costs associated with 
advanced cardiovascular disease (Russell JC 2001). 
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Table 4.1: Approaches to the treatment of the metabolic syndrome 
• Multi-factorial behavioural changes 
• Therapeutic lifestyle interventions 
> Increased physical activity 
> Weight reduction 
> Prudent diet 
Increase intake of fruits and vegetables 
•:• Decreased intake of saturated fats 
•:• Increased intake of foods with decreased glycaemic index 
• Pharmacological therapy 
> Aspirin 
> Antihypertensive therapy (RAAS Blockers) 
> Lipid lowering therapy 
> Insulin Sensitisers. 
4.2.2 Early Diagnosis 
Given the slow, asymptomatic development of cardiovascular disease in the 
metabolic syndrome, a rational approach to the growing incidence of overt type 2 
diabetes and the associated cardiovascular disease is early diagnosis and preventative 
treatment. This implies effective screening for the early stages of disease progression 
even in the absence of any clinically significant disease. The target population of 
interest consists of both genders having abdominal obesity, a factor that can most 
efficiently and accurately be identified by measuring waist circumference. 
Individuals with elevated plasma insulin, impaired glucose and an excessive insulin 
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response can be identified using the relatively simple oral glucose tolerance test. 
Other routine laboratory tests should reveal dyslipidaemia, hyperuricaemia and 
microalbuminuria. As demonstrated in this study, most of these metabolic syndrome 
traits can be easily detected at any clinical setting. These identified individuals 
should then be at high priority for dietary, exercise, and pharmacological intervention. 
However, from our study (as seen in the control group) and other clinical trials 
(Swinbum BA et al 2001，Wing RR et al 2001)，this patient group will not show 
significant and lasting metabolic improvement without effective pharmacological 
treatment. This is because while weight loss is achievable in the short-term (6-12 
months) once the intensive intervention ends, people drift back to their original 
weight. 
4.2.3 Lifestyle modification 
# 
Weight reduction and regular physical activity are key elements for prevention 
and care of metabolic syndrome. Although no particular diet plan or dietary 
composition has been studied specifically in relation to the metabolic syndrome, the 
current dietary recommendations, as we had recommended to our study population, 
include a balanced low-energy diet containing, fruits，vegetables, whole grains, fish, 
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and lean meats while minimizing fats, salt, simple sugars and highly processed foods 
(Miranda PJ et al 2005). 
Data from the Finnish Diabetes Prevention Study group (522 subjects) 
concluded that the risk of type 2 diabetes mellitus could be reduced by 58% 
compared with the control group by instituting therapeutic lifestyle changes in 
patients with the metabolic syndrome. The therapeutic lifestyle changes in the 
intervention group (265 subjects) consisted of specific dietary instructions and 
moderate exercise of > 30 min/day (3.5 hours/week) but subjects in the control group 
were not offered any specific individualized programs. At the mean duration of 3.2 
years, the incidence of impaired glucose tolerance progressing to type 2 diabetes 
mellitus is 3% per year in the intervention group and 6% per year in the control 
group. 
The Diabetes Prevention Program, Da Qing study, Stop-NIDDM trial and 
TRIPOD trial have also confirmed that diabetes is preventable, and insulin resistance 
is decreased by weight loss or exercise, or both (Table 4.2). 
In this study, in the control group, four patients who were diagnosed as IGT at 
the start of therapy became normoglycaemic at the end of the study, with one 
progressed from diabetes to IGT. This shows that even simple lifestyle intervention 
is important in slowing the progression of diabetes in high-risk patients. 
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Table 4.2. Diabetes Prevention Trials 
Study Intervention Risk  
Reduction (%) 
Finnish Diabetes Prevention Study Lifestyle Changes 58 
Da Qing Study Lifestyle Changes 3 1 - 4 0 
Diabetes Prevention Program Lifestyle Changes, 53 
Metformin 31 
T R I P O D Troglitazone 55 
STOP-NIDDM Trial Acarbose 25 - 36 
WOSCOPS Pravastatin 30 
H O P E Ramipril 34 
TRIPOD = Troglitazone in the Prevention of Diabetes; STOP-NIDDM = Study to 
Prevent Non-Insulin-Dependent Diabetes Mellitus; WOSCOPS = West of Scotland 
__Coronar^^Prevgntion Study; HOPE = Heart Outcomes Prevention Evaluation 
Table 4.3. Coronary Artery Disease (CAD) Prevention Trials with Statins in 
Subjects with Diabetes 
CAD Risk Reduction (%) 
Study Statin Subjects (N) Overall Diabetes 
HPS Simvastatin 20 536 25 -30 2 2 - 3 3 
CARE Pravastatin 589 23 25 
4S Simvastatin 202 32 55 
HPS = Heart Protection Study; CARE = Cholesterol and Recurrent Events trial; 
4S = Scandinavian Simvastatin Survival Study.  
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4.2.4 Pharmacological Targets 
4.2.4.1 Statins 
As discussed in Chapter 1，the metabolic syndrome is commonly associated 
with hyperinsulinaemia and a specific abnormal lipid profile, i.e. elevated plasma 
triglycerides (Carlson LA 1979)，low HDL-cholesterol (Castelli WP 1986)，and 
increased VLDL-cholesterol (Stamler J 1986)，all of which can predispose to the 
development of atherosclerosis. Despite the gaps in our understanding, it is clear that 
effective reduction of the insulin levels and the accompanying VLDL 
hyperlipidaemia is the first step towards a final therapeutic goal. 
In the NCEP report published in July 2004, the coordinating committee of the 
National Cholesterol Education Program reviewed recent clinical trials for the NCEP 
ATP II guidelines and recommended the initiation of statins in diabetic patients, 
especially those with cardiovascular disease (Grundy et al 2004). The benefits of 
statin therapy in people with diabetes have been observed from the post hoc 
subgroup analysis of 3 major statin trials (Table 4.3). Patients with diabetes who 
received pravastatin or simvastatin had fewer coronary artery disease events. 
Although statins do not alter insulin resistance, the WOSCOPS study (Shepherd J et 
al 1995) showed that patients treated with pravastatin had a lower incidence of new-
onset type 2 diabetes mellitus compared to those on placebo (Table 4.2). In addition, 
Page 92 
Chapter 4 Discussion & Conclusion 
the HPS support an aggressive immediate approach for the metabolic syndrome, with 
statin therapy to stabilize at-risk atherosclerotic plaques. The multifactorial regimen 
of diet，exercise, and statin therapy, therefore, is highly recommended. 
4.2.4.2 Fibrates 
Drugs in the fibric acid group, including clofibrate, gemfibrozil and 
fenofibrate, reverse the dyslipidaemia associated with the metabolic syndrome. In the 
Diabetic Atherosclerosis Intervention Study (DAIS) (Steiner G 2001)，a 
multinational angiographic study of individuals with type 2 diabetes mellitus, 
fenofibrate-treated subject HAD a 10% reduction in the levels of total cholesterol, 
7% decrease in LDL, 6% increase in HDL and a 30% reduction in plasma 
triglyceride levels. 
4.2.4.3 ACE Inhibitors 
In the HOPE study (Yusuf S et al 2001) , the ACE inhibitor ramipril was 
studied to examine its effectiveness in reducing macrovascular and microvascular 
effects in 3654 diabetic patients and 5720 non-diabetic patient. Ramipril reduced the 
risk of development of diabetes (primary prevention) by 34% (Table 4.2), exact 
mechanism on how it does it is unknown. 
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4.2.4.4 Thiazolidinediones 
The early stages of metabolic syndrome consist primarily of insulin resistance 
with glucose intolerance or overt type 2 diabetes mellitus. These metabolic syndrome 
patients are likely to be seen by primary care providers. Since clinicians now 
recognize diabetes mellitus as a cardiovascular disease risk equivalent, in applying 
the ATP III guidelines, clinicians need to consider both the hyperglycaemia and the 
cardiovascular sequelae associated with insulin resistance. Hence, insulin sensitisers 
are indicated as the primary prevention in treating insulin resistance. 
In the TRIPOD Study (Buchanan et al 2002), involving 236 Hispanic women 
with previous gestational diabetes, there is a 55% relative reduction in diabetes 
progression. Even after a washout period of 8 months, the preventive effects of the 
drugs were still observed. Therefore, it is possible that troglitazone may affect the 
natural history of glucose intolerance and may actually prevent diabetes in certain 
patients, rather than simply delaying its onset. 
No clinical trial data to date support the use of pharmacological agents to 
improve insulin sensitivity in non-diabetic subjects, although this is an area of active 
interest. In our study, which included non-diabetic patients with glucose intolerance, 
the results of rosiglitazone were promising. The number of patients who were 
previously diagnosed as having diabetes dropped in the rosiglitazone group. 
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Surprisingly, there is a rise in the number of patients having the metabolic syndrome 
in the rosiglitazone group. However, as consistent with its pharmacological effects as 
an insulin-sensitiser, six diabetic patients were diagnosed as IGT while another six 
who were IGT became normoglycaemic. These results indicate that rosiglitazone 
may have some potential in delaying the onset of type 2 diabetes in high-risk patients. 
Although the insulin sensitizing effects of rosiglitazone may not be as apparent 
due to the small sample size, there is an obvious trend of improvement, indicating a 
possibility in reducing cardiovascular risk associated with metabolic syndrome. The 
favourable lipid profile and low incidence of adverse effects provide overall benefits 
to patients beyond blood glucose control. Although in this study, total cholesterol 
increases in general, there is a drop in triglycerides and the increase in LDL-
cholesterol increased. Even though LDL particle size is not measured in this study, it 
has been shown that rosiglitazone changes the LDL particles from predominantly 
small and dense (ie, a more atherogenic profile) to larger, more buoyant and less 
atherogenic particles (Lebowitz HE 2002). As a result of this shift, the ratio ofLDL-
cholesterol to apolipoprotein B increases, therefore, plasma LDL-cholesterol 
concentration increases by 11% in this study. When compared with other anti-
diabetic agents, these improved efficacy measures and additional benefits should 
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have long-term clinical and economic effects when projected over the lifetime of a 
patient with metabolic syndrome eventually progressing to diabetes. 
Published reports suggest that pioglitazone and rosiglitazone have different 
effects on lipids in patients with type 2 diabetes (King AB 2000, Boyle PJ et al 2002, 
Khan MA et al 2002, Olansky L et al 2003). However, these studies were either 
retrospective chart reviews or clinical trials not rigorously controlled for concomitant 
glucose- and lipid-lowering therapies. Goldberg RB and colleagues recently 
published a study comparing the lipid and glycaemic effects of pioglitazone and 
rosglitazone in patients with type 2 diabetes and dyslipidaemia (Goldberg RB et al 
2005). It was shown that triglycerides decreased with pioglitazone but increased with 
rosiglitazone instead. The increase in HDL-cholesterol was also greater with 
pioglitazone and the increase in LDL-cholesterol was less than rosiglitazone. LDL 
particle size increased more with pioglitazone too. These findings showed that both 
thiazolinediones had different effects on plasma lipids independent of glycaemic 
control or concomitant lipid-lowering or other antihyperglycaemic therapy. When 
compared with rosiglitazone, pioglitazone may have more favourable effects on lipid 
profiles, but whether these differences translate into differences for the risk of CVD 
is not clear. 
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4.2.4.4.1 Economic Evaluation of Thiazolidinediones 
There are no published economic studies on rosiglitazone. However, Coyle 
D and colleagues conducted an economic evaluation of pioglitazone in the 
management of type 2 diabetes mellitus in Canada. Using a Markov model to 
determine the health outcomes and economic impact from the prospective of a 
provincial ministry of health, it compared treatment strategies with different first-line 
therapies: pioglitazone, glibenclamide, metformin, diet and exercise. The 
pioglitazone-based strategy was estimated to reduce the cumulative incidence of 
severe clinical events and long-term complications by between 23 and 36% and to 
increase discounted life expectancy by between 0.13 and 0.35 life-years. The 
discounted incremental cost per life-year gained of a first-line pioglitazone-based 
strategy was 54 000 Canadian dollars ($Can) compared with metformin, $Can 42 
000 compared with glibenclamide and $Can 27 000 compared with diet and exercise. 
As thiazolinediones is a more effective treatment for type 2 diabetes mellitus 
and even metabolic syndrome, it can be projected that this agent may be cost 
effective for certain patients and may delay the onset of insulin use, which has 
significant effects on the quality of life. However, ideally, long-term studies are 
required to support the cost-effectiveness of agents in this class. 
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4.2.4.5 Orlistat 
Heymsfield SB et al 2000 conducted a retrospective pooled analysis of three 
double-blind, randomized, placebo-controlled 2-year trials (Hauptman J et al. 2000’ 
Sjostrom L et al 1998，Davidson MH et al, 1999)，675 obese patients IGT patients, 
71.6% who were treated with orlistat (n = 359) had normal glucose tolerance at the 
end of treatment compared with 49.1% (n = 316) in the placebo group (p = 0.04). 
Also, orlistat recipients had a greater reduction in fasting serum insulin levels and 
insuliiiAuc. However, in patients classified as diabetes mellitus at baseline, the 
change in fasting serum insulin levels significantly favoured placebo recipients 
instead. But in patients with normal glucose tolerance at baseline, compared with 
placebo, the change from the insuliriAuc significantly favoured orlistat (Table 4.4). In 
addition, fasting serum glucose levels and the glucoseAuc had a greater reduction in 
orlistat when compared to placebo recipients. In the normal glucose tolerance group 
and IGT group, the reduction from baseline was significantly greater in orlistat than 
placebo recipients. 
These results were consistent in the XENDOS study (Togerson JS et al, 2004) 
whereby at the end of the 4-year study, the cumulative incidence of diabetes was 
9.0% with placebo and 6.2% with orlistat, corresponding to a risk reduction of 37.3% 
(p = 0.0032). Treatment with orlistat plus lifestyle changes also resulted in early and 
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significant improvements that were sustained throughout the study (Table 4.5). Total 
and LDL-cholesterol decreased significantly more with orlistat than placebo, at both 
1 and 4 years. 
In the XENDOS study, adding orlistat to lifestyle changes produced more 
weight loss and led to a significantly lower risk of developing type 2 diabetes. It also 
demonstrated that a weight loss agent in combination with lifestyle changes over 4 
years is of greater benefit than lifestyle changes alone for producing long-term 
weight loss and improvements in cardiovascular risk factors. 
In this study, four patients progressed from type 2 diabetes to IGT while one 
IGT patient became normoglycaemic. There is also a drop in the number of patients 
with the metabolic syndrome. This is consistent with the findings established by 
XENDOS and Heymsfield SB et al, suggesting that orlistat may be a useful treatment 
option in the lowering the risk of developing type 2 diabetes in high-risk patients. It 
has been shown in this study that the impact of orlistat on lipid parameters was 
independent of the magnitude of weight loss but was greater in the orlistat group than 
























































































































































































































































































































































































































































































































































































































































































































































































































































































Chapter 4 Discussion & Conclusion 
Although orlistat produced significant reductions in most anthropometric 
parameters, such effect was not observed in the lipid profile. This is consistent with 
the findings by Hollander PA et al 1998 and XENDOS. On the other hand, there is 
no apparent pharmacologic basis for treatment using orlistat compared to lifestyle 
interventions on parameters of glycaemic control. Indeed, more patients lost a greater 
amount of weight in the orlistat-treated group, but the relationship between degree of 
weight loss and improvement in glycaemic control is well-established as discussed 
earlier. 
4.2.4.5.1 Economic Evaluation of Orlistat 
Much can be gained economically by reducing bodyweight to help patients 
gain better control of their fasting plasma glucose (FPG) and glycosylated 
haemoglobin Aic(HbAic) values. However, most type 2 diabetes medications cause 
weight gain, and have been shown to aggravate blood glucose control and decrease 
the clinical effectiveness of treatment (DeFronzo RA 1999). 
Orlistat therapy yielded cost savings in a modeling study, available as an 
abstract (Lee KK et al 2001). It was estimated that in IGT patients, 1.9% of orlistat 
recipients would progress to type 2 diabetes, as compared with 8% of patients 
receiving dietary therapy alone. At the end of the 1 year's treatment, the total cost of 
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managing diabetes mellitus was estimated to be $HK8187 and $HK34 469 in 
recipients of orlistat plus dietary therapy and dietary therapy alone, respectively. 
After 2 years' treatment, the total cost of managing diabetes mellitus was $HK23 390 
and $HK100 123 in the corresponding treatment groups. 
Maetzel A et al 2003 used the Markov state transition model to evaluate the 
cost effectiveness of orlistat in addition to standard type 2 diabetes treatment 
(sulphonylureas, metformin, or insulin plus diet and physical activity) in the 
treatment of overweight and obese patients with type 2 diabetes in a US-based 
healthcare setting from the perspective of the healthcare provider. It demonstrated 
that treatment with orlistat increased event-free life expectancy by 0.13 years over 
11-year period. Average treatment costs were estimated to be $US19 987 in the 
orlistat group compared with $US18 865 in the group that received diabetes 
medication and weight management alone. This translated into a cost-effectiveness 
ratio of $US8327 per event-free life-year gained. The authors concluded that adding 
orlistat as a pharmacological treatment to conventional diabetes and weight 
management approaches seems to be a cost-effective treatment option for overweight 
and obese patients with type 2 diabetes. 
A Belgian analysis found orlistat to be cost-effective, costing $US2996 per 
life-year gained in patients with type 2 diabetes, hypertension and 
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hypercholesterolaemia and $US17 298 per life-year gained (2000 values) in patients 
with diabetes alone (Lamotte M et al 2002). 
As healthcare costs have continued to rise, the issues of cost and cost 
effectiveness for both the health system and society have become increasingly 
important. The above studies demonstrated that it might be viable and economical to 
use orlistat to treat the metabolic syndrome in the long run. 
4.3 Limitations of the study 
4.3.1 Small sample size 
This study was limited by a small sample size of 63 participants of which 58 
(92%) completed the study. During the period of study, the outbreak of the Severe 
Acute Respiratory Syndrome (SARS) occurred and Hong Kong is very badly 
affected. There is difficulty in patient recruitment as people shunned away from 
hospitals. 
Although a treatment trend may be seen in many parameters such as HbAlc, 
FPG，triglycerides, HDL-cholesterol and waist circumference differences, there is no 
statistical significance. In comparison, other clinical trials such as those conducted by 
Lebovitz HE et al 2001 and the XENDOS study showed significant changes in these 
parameters. The sample size employed in these studies is very much bigger (n = 169 
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and n = 1487 respectively), perhaps explaining why such results were not reflected in 
this study. 
4.3.2 Short period of study 
Both patient recruitment and treatment regimen took around 7 months and the 
study was ended in approximately three years although this is a six-months study. 
The reason for the long duration of the study was mainly due to the occurrence of 
SARS outbreak, which resulted in an approximately eight-month break in patient 
recruitment until the situation improved. The effects of treatments (lifestyle 
intervention especially) on reducing clinical cardiovascular events may be more 
apparent if the duration of study is longer as reflected in the UKPDS, DPP and 
XENDOS. 
4.3.3 Adherence to lifestyle modifications 
A dietitian recommended a low caloric diet and > 30-minute daily aerobic 
exercise regimen was advised after patient recruitment. These recommendations 
were emphasised at every patient visit. However, we do not have any suitable tools 
to monitor the patient adherence to these recommendations, and there is a lack of 
documentation of dietary habits and physical activity. That is why there was no 
Page 105 
Chapter 4 Discussion & Conclusion 
significant weight loss over a period of six months for the lifestyle intervention, in 
contrast to other clinical trials such as UKPDS and DPP. 
4.3.4 Analytical assays 
Due to the limited amount of finance available, the analytical assays of each 
patient's plasma glucose and insulin levels after 75g-OGTT was performed once 
with no repeats conducted, exposing the results to chance. Therefore, the conclusions 
related were based on a single test result and may not be as convincing. 
4.3.5 Follow up after end of study 
A follow up after the end of the study may be able to address issues such as the 
sustainability of treatments and long-term adverse events, but limitations set by 
increasing costs of study medications and laboratory analysis restricted the scope of 
the study. Also, part of the patients recruited earlier refused to be followed-up during 
the SARS outbreak. 
4.3.6 Ultrasound measurement of the Common Carotid Arteries 
There is no statistical power conducted for the common carotid arteries in this 
study, which explained why the results were all insignificant. Although such 
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measurement is not readily available in usual clinical practice, it may provide some 
useftil insights into the progression of CVD in insulin resistant patients. However, 
the period of six months may not show the build up of atherosclerotic plaques as the 
time frame is too short for deposition of plaques. 
4.3.7 Availablity of thiazolinediones 
There is two thiazolinediones available, pioglitazone and rosiglitazone. In Hong 
Kong, pioglitazone is only restricted to a certain public hospital and is not widely 
available. Therefore, rosiglitazone is employed in this study instead. However, recent 
papers suggested that pioglitazone and rosiglitazone have significantly different 
effects on plasma lipids independent of glycaemic control. Pioglitazone compared 
with rosiglitazone is associated with significant improvements in triglycerides and 
HDL-cholesterol (Goldberg RB et al 2005，Khan MA et al 2002). 
4.4 Conclusion and Implications for future studies 
The challenges faced by clinicians involved early detection of insulin resistance 
and implementation of treatment strategies that encompass all components of the 
metabolic syndrome. There is a need to shift the focus in the diagnosis and treatment 
of the metabolic syndrome from glucose control to primary prevention, early 
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detection, and treatment of the underlying atherogenic risk factors. This will then 
prevent the progression of type 2 diabetes mellitus and cardiovascular disease. 
Recognition of the relationship between cardiovascular disease and the 
metabolic syndrome has led to emphasis on appropriate treatment for the metabolic 
syndrome. To prevent progression to type 2 diabetes mellitus and its complications, 
lifestyle changes are essential, including dietary therapy and exercise. Drugs which 
can affect more than one aspect of this syndrome maybe of real value. The potential 
sparing effects of thiazolidinediones on pancreatic p-cells as well as prevention of 
diabetes and its complications are promising. This study suggest that with 
improvements on dyslipidaemia and its insulin-sensitising effects, patients with IGT 
or type 2 diabetes may respond better to a thiazolinedione as opposed to orlistat or 
lifestyle intervention. In addition, the thiazolidinediones as monotherapy do not 
appear to be associated with significant hypoglycaemia or gastrointestinal 
disturbances. However, comparative clinical studies are needed to clarify whether 
treatment outcomes with an insulin-sensitiser differ from current therapies. There are 
no peer-reviewed data available on the long-term effects of the use of 
thiazolidinediones or much prospective randomized-clinical trials published 
comparing rosiglitazone with pioglitazone. Further studies regarding the direct head-
to-head comparisons of the thiazolidinediones in combination with metformin or 
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sulphonylurea would also be of interest. The impact of the thiazolidinediones in 
delaying transfer to insulin and the impact on long-term outcomes should also be 
considered for investigation. 
Orlistat，with its effect on weight, blood pressure, lipids and glucose, may be 
one of the first drugs that could be placed in the category of a 'metabolic therapeutic 
agent，(Hollander PA 2002). In accordance to many studies mentioned earlier, this 
study indicated that even modest weight loss, facilitated pharmacologically or not, 
produces important metabolic benefits. However, as shown in this study and in the 
XENDOS study, the addition of a pharmacological treatment with orlistat may be a 
useful adjunct to dietary and lifestyle intervention in preventing or delaying the onset 
of type 2 diabetes in obese subjects with IGT or type 2 diabetes. Further long-term 
studies are required to established if the glycaemic, lipid and insulin secretory 
metabolic effects of orlistat are sustained and whether the agent has a 
pharmacological role in reducing cardiovascular event rates in individuals with the 
metabolic syndrome. 
Future studies should be also undertaken to observe the effects of using both 
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INFORMED CONSENT FORM 
同意書 
Study Title: The effect of Orlistat and Rosiglitazone on insulin action in a group of Chinese 
patients affected by the metabolic syndrome - a randomized, single-blinded and 
placebo-controlled study 
研究項目： 赛尼可 (Or l i s ta t )及羅西格列酬 (Ros ig l i tazone)對代謝綜合徵患者膜島素功能之作用_ 
一個隨機¥•肓安慰劑對照之臨床研究 
Volunteer自願參加者 
I, HKID No.  
address:  
hereby state that I have read the subject information sheet and I have been fully advised the nature, 
purpose, procedure and possible risks of the study and have been given the opportunity to question the 
doctor concerned on all aspects of the study. I understand what is involved and give my consent to 





Signature of volunteer 志願者簽名： Signature of witness見証人簽名： 
D a t e日期： Da te曰期： 
Investigator 者 
I hereby state that I have fully explained the nature, purpose, procedure and possible risks of the 
participation in this study to the above signed. 
本人在此聲明 :我已將有關此項研究的性質 ,目的 ,過程和可能發生的問題等向以上簽署作了全部解釋。 
Signature of investigator 研究者簽名： Date 曰期： 
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APPENDIX III : Clinical Record Form (CRF) 
Name: ID No.: Tel No.:  
Gender: Age: D.O.B:  
Screening #: Consent: Y e s / N o Randomisation #: 
Date: Visit #: 
Body Weight: kg Body Height: ^ BMI: kg/nr 
Time:  





Urine Test: Protein: Glucose: RBC: Ketone: pH:  
Drug Allergy:  
Blood Test today; Dietary Advice: Y / N MRl Scan: Y/ N 
O G T T : Y / N Urine Pregnancy Tes t : Y / N / NA Physical Examination: Y/ N 
Past Medical History:  
Current Medications:  
Adverse Events: 
Symptom: 1. 2. 3. 
Date Started: 1. 2. 3. 
Treatment: 1. 2. 3. 
End Date: 1. 2. 3.   
Study Drug Given: Morning: Lunch: Dinner: 
Study Drug Returned: Morning: Lunch: Dinner 
Study Drug Missed: Morning: Lunch: Dinner: 
Compliance: 
Investigator's comments:  
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